Section A1 Applicant

Annex Point IIA1

1.1	**Applicant**	**Name:** European Union IPBC Task Force (Arch Chemicals, Bayer Chemicals, Sostram Corp., Troy Corp.), c/o SCC GmbH **Address:** [redacted] **Telephone:** [redacted] **Fax number:** [redacted] **E-mail address:** [redacted]
1.2	**Manufacturer of Active Substance** (if different)	Confidential information: Please refer to the "Confidential Data File"
1.3	**Manufacturer of Product(s) (if different)**	Not applicable: The Product Dossier is based on two model formulations.
	1) Product 1	
	2) Product n	

Section A2 Identity

Please refer to the "Confidential Data File" for information on Identity of IPBC for each Task Force Member.

Section A3 Physical and Chemical Properties of Active Substance

Subsection (Annex Point)	Method	Purity/ Specification	Results Give also data on test pressure, temperature, pH and concentration range if necessary	Remarks/ Justification	GLP (Y/N)	Reliability	Reference	Official use only
3.1 Melting point, boiling point, relative density (IIA3.1)								
3.1.1 Melting point								
Melting pt. 1	EEC Directive 92/69 A 1	As given in section 2	**result: 63.6 °C pressure: ambient**	Method: Differential Thermal Analysis (DTA)	Y	1	112-001 A3.1.1/01	
Melting pt. 2	OECD 102	As given in section 2	**result: 64.7 – 66.3 °C pressure: ambient**	Method: Capillary tube	Y	1	112-002 A3.1.1/02	
Melting pt. 3	EPA subdivision D series 63-5	Not exactly given (≈ 98 %) This does not influence the integrity of the study	**result: 65.5 – 66 °C pressure: ambient**	Method: Capillary tube	Y	1	119-001 A3.1.1/03	
Melting pt. 4	OPPTS830-7200	Not given	**result: 68.0 – 69.5 °C pressure: ambient**	Method: Capillary tube	Y	1	119-002 A3.1.1/04	
3.1.2 Boiling point								
Boiling pt.	EEC Directive 92/69 A 2	As given in section 2	**result: no boiling point pressure: ambient**	Method: Differential Thermal Analysis (DTA) Decomposition of the test substance starts at 85 °C	Y	1	112-001 A3.1.1/01	
3.1.3 Bulk density/ relative density								

Section A3 Physical and Chemical Properties of Active Substance

Subsection (Annex Point)	Method	Purity/ Specification	Results Give also data on test pressure, temperature, pH and concentration range if necessary	Remarks/ Justification	GLP (Y/N)	Reliability	Reference	Official use only
rel. density 1	EEC Directive 92/69 A 3	As given in section 2	**1.714 (at 20 °)**	Pyknometer method	Y	1	112-001 A3.1.1/01	
rel. density 2	In line with OECD 109	Not given	**1.767 (ambient temperature)**	Pyknometer method	Y	2	113-001 A3.1.3/01	
rel. density 3	EPA subdivision D series 63-7	Not exactly given (≈ 98 %) This does not influence the integrity of the study	**1.59 (at 20 °)**	Pyknometer method	Y	1	119-001 A3.1.1/03	
rel. density 4	OPPTS 830.7300	Not given	**1.672 (at 20 °)**	Pyknometer method	Y	1	119-002 A3.1.1/04	
3.2 Vapour pressure (IIA3.2)								
Vapour pressure 1	EEC Directive 92/69 A 4	As given in section 2	**temperature: 20 °C result: 1.04 x1 0^{-3} Pa temperature: 25 °C result: 2.36 x 10^{-3} Pa**	Vapour pressure balance method	Y	1	115-001 A3.2/01	
Vapour pressure 2	EEC Directive 92/69 A 4 OECD 104 EPA OPPTS No. 830-7950	As given in section 2	**temperature:2 0 °C result: 3.8 x 10^{-3} Pa temperature: 25 °C result: 4.5 x 10^{-3} Pa**	Vapour pressure balance method	Y	1	115-002 A3.2/02	
Vapour pressure 3	EPA subdivision D series 63-9	As given in section 2	**temperature: 25 °C result: 1.43 x 10^{-3} Pa**	Gas saturation method	Y	1	119-001 A3.1.1/03	

Section A3 Physical and Chemical Properties of Active Substance

Subsection (Annex Point)	Method	Purity/ Specification	Results Give also data on test pressure, temperature, pH and concentration range if necessary	Remarks/ Justification	GLP (Y/N)	Reliability	Reference	Official use only
3.2.1 Henry's Law Constant (Pt. I-A3.2)	Calculated parameter	n.r.	**calculated result:** **3.38 x 10^{-3} Pa m^3 mol^{-1}** **6.45 x 10^{-3} Pa m^3 mol^{-1}** **2.05 x 10^{-3} Pa m^3 mol^{-1}** **at 25 °C temperature**	Calculated with the vapour pressures 1-3 2.36 x 10^{-3} Pa 4.5 x 10^{-3} Pa 1.43 x 10^{-3} Pa and an extrapolated solubility of 196 mg/L at 25 °C (see Annex point 3.5, water solubility 2	N	1	115-004 A3.2.1/01	
3.3 Appearance (IIA3.3)								
3.3.1 Physical state	EPA subdivision D series 63-3	Not exactly given (≈ 98 %) This does not influence the integrity of the study	**Crystalline solid, very fine needles**		Y	1	119-001 A3.1.1/03	
		Not given	**Powdered solid**		Y	1	119-002 A3.1.1/04	
3.3.2 Colour	EPA subdivision D series 63-2	Not exactly given (≈ 98 %) This does not influence the integrity of the study	**Off-white to very pale yellow**		Y	1	119-001 A3.1.1/03	

Section A3 Physical and Chemical Properties of Active Substance

Subsection (Annex Point)	Method	Purity/ Specification	Results Give also data on test pressure, temperature, pH and concentration range if necessary	Remarks/ Justification	GLP (Y/N)	Reliability	Reference	Official use only
		Not given	**Off white Munsell Color System: 5Y (9/1)**	Based on Munsell Color System	Y	1	119-002 A3.1.1/04	
3.3.3 Odour	EPA subdivision D series 63-4	Not exactly given (≈ 98 %) This does not influence the integrity of the study	**A faint odour of iodine**		Y	1	119-001 A3.1.1/03	
		Not given	**odourless**		Y	1	119-002 A3.1.1/04	
3.4 Absorption spectra (IIA3.4)								
UV/VIS IR NMR MS	Not indicated	As given in section 2	**A UV/VIS-,IR- and NMR spectra confirm the molecular structure.**		Y	1	117-001 A3.4/01	
UV/VIS IR NMR MS	Not indicated	Not given	**A UV/VIS-,IR- and MS spectra confirm the molecular structure.**		N	1	117-002 A3.4/02	
UV/VIS IR NMR MS	Not indicated	Not given	**A NMR spectrum confirms the molecular structure.**		N	1	117-003 A3.4/03	

Section A3 Physical and Chemical Properties of Active Substance

Subsection (Annex Point)	Method	Purity/ Specification	Results Give also data on test pressure, temperature, pH and concentration range if necessary	Remarks/ Justification	GLP (Y/N)	Reliability	Reference	Official use only
UV/VIS **IR** **NMR** **MS**	Not indicated	The purity of the test substance was slightly lower than given in the specification in section 2. This does not influence the integrity of the study	**A UV/VIS spectrum confirms the molecular structure. Two wavelength maxima were observed at 191 nm and 227 nm. Extinction coefficients ε for 191 nm:** **pH 5 ε=479 Lmol^{-1}cm^{-1}** **pH 7 ε=489 L mol^{-1}cm^{-1}** **pH 9 ε=500 L mol^{-1}cm^{-1}** **for 227** **pH 5 ε=6570 L mol^{-1}cm^{-1}** **pH 7 ε=6050 L mol^{-1}cm^{-1}** **pH 9 ε=6080 L mol^{-1}cm^{-1}**	Sample solution prepared in acetonitrile/water (1:1 v/v)	Y	1	117-004 A3.4/04	

Section A3 Physical and Chemical Properties of Active Substance

Subsection (Annex Point)	Method	Purity/ Specification	Results Give also data on test pressure, temperature, pH and concentration range if necessary	Remarks/ Justification	GLP (Y/N)	Reliability	Reference	Official use only
3.5 Solubility in water (IIA3.5)								
Water solubility 1	OPPTS No.:830.7840	Not given	**result: 166 mg/L temperature: 20 °C pH: neutral**	Flask method	Y	2	114-001 A3.5/01	[redacted]
Water solubility 2	EEC Directive 92/69 A 6	As given in section 2	**result: 182 mg/L temperature: 20 °C pH: 4.0 result: 168 mg/L temperature: 20 °C pH: 7.0 result: 176 mg/L temperature: 20 °C pH: 9.0 result: 110 mg/L temperature: 10 °C pH: 7.0 result: 216 mg/L temperature: 30 °C pH: 7.0**	Flask method No significant influence of the pH value, but an slight increase of the water solubility with temperature rise could be observed.	Y	1	114-002 A3.5/02	
Water solubility 3	Not given	radiolab. IPBC 3-iodo-2-propynyl-N[1-^{14}C]-butyl-[^{14}C]-carbamate	**result: 213 mg/L temperature: 25 °C pH: 5.0 result: 202 mg/L temperature: 25 °C pH: 7.0 result: 195 mg/L temperature: 25 °C pH: 9.0**	Similar to flask method	Y	2	114-004 A3.5/03	[redacted]

Section A3 Physical and Chemical Properties of Active Substance

Subsection (Annex Point)	Method	Purity/ Specification	Results Give also data on test pressure, temperature, pH and concentration range if necessary	Remarks/ Justification	GLP (Y/N)	Reliability	Reference	Official use only
Water solubility 4	EPA subdivision D series 63-8	Not exactly given (≈ 98 %) This does not influence the integrity of the study	**result: 174 mg/L temperature: 20 °C pH: neutral**	Flask method	Y	1	119-001 A3.1.1/03	
3.6 Dissociation constant (-)	OECD 112		**No result available**	Water solubility of IPBC is to low for a determination	Y	1	115-003 A3.6/01	
3.7 Solubility in organic solvents, including the effect of temperature on solubility (IIIA3.1)	OPPTS No.:830.7840	Not given	**Octanol Result: 150 g/L temperature: 20 °C Petroleum Ether Result: 3.6 g/L temperature: 20 °C Methanol Result: > 1000 g/L temperature: 20 °C**	Flask method	Y	2	114-001 A3.5/01	
	EPA subdivision D series 63-8	Not exactly given (≈ 98 %) This does not influence the integrity of the study	**Heptane Result: 3.5 g/L temperature: 20 °C ethyl acetate Result: 281 g/L temperature: 20 °C**	Flask method	Y	1	119-001 A3.1.1/03	

Section A3 Physical and Chemical Properties of Active Substance

Subsection (Annex Point)	Method	Purity/ Specification	Results Give also data on test pressure, temperature, pH and concentration range if necessary	Remarks/ Justification	GLP (Y/N)	Reliability	Reference	Official use only
3.8 Stability in organic solvents used in b.p. and identity of relevant breakdown products (IIIA3.2)	Not relevant (No standard guideline for this kind of test available)	Not given	**Stable in octanol, petroleum ether and methanol for 9 days when stored at 25 °C**	Concentration of the stored solutions: Petroleum ether and methanol: ≥10 % of the saturation level, octanol < 10 % of the saturation level	Y	2	114-001 A3.5/01	[redacted]

Section A3 Physical and Chemical Properties of Active Substance

Subsection (Annex Point)	Method	Purity/ Specification	Results Give also data on test pressure, temperature, pH and concentration range if necessary	Remarks/ Justification	GLP (Y/N)	Reliability	Reference	Official use only
	Not relevant (No standard guideline for this kind of test available)	Not exactly given (≈ 98 %) This does not influence the integrity of the study	**Stable in octanol, heptane and ethyl acetate for 96 h, storage at ambient conditions**	a high and a low concentration was tested	Y	1	119-001 A3.1.1/03	
3.9 Partition coefficient n-octanol/water (IIA3.6)	Effect of pH (5 to 9) not required, because IPBC is neither an acid nor a base.							
log Pow 1	EEC Directive 92/69 A 8	As given in section 2	**result: 2.4 temperature: 35 °C pH: 6.4**	HPLC method Deviation from guideline: 35 °C instead of 25 °C. The influence of the different temperature on the measured log P lies within the range of the error of the method.	Y	1	114-003 A3.9/01	
log Pow 2	OECD 107	As given in section 2	**result: 2.81 temperature: 25 °C pH: neutral**	Flask shaking method	Y	1	114-005 A3.9/02	
log Pow 3	EPA subdivision D series 63-8	As given in section 2	**result: 2.88 temperature: 21 °C pH: about 7**	Flask shaking method	Y	1	119-001 A3.1.1/03	

Section A3 Physical and Chemical Properties of Active Substance

Subsection (Annex Point)	Method	Purity/ Specification	Results Give also data on test pressure, temperature, pH and concentration range if necessary	Remarks/ Justification	GLP (Y/N)	Reliability	Reference	Official use only
3.10 Thermal stability, identity of relevant breakdown products (IIA3.7)	EPA subdivision D series 63-17	As given in section 2	**The substance is stable at room temperature.**	After one year of storage at 25 °C, assay values of the test substance remained constant within the limits of the analytical precision.	Y	1	146-002 A3.10/01	[redacted]
	OPPTS 830.6317 GIFAP Technical Monograph No.17	As given in section 2	**The test substance is stable at 35 °C for 12 weeks.**	The test substance showed no degradation when stored over a 12 week incubation period at 35 °C.	Y	1	146-003 A3.10/02	[redacted]
	OPPTS 830.6317	As given in section 2	**The test substance is stable at 54 °C for 14 days.**	When stored at 54 °C for 14 days the test substance decreased by not more than 5 per cent.	Y	1	146-005 A3.10/03	[redacted]
3.11 Flammability, including auto-flammability and identity of combustion products (IIA3.8)	EEC Directive 92/69 A 10 flammability A 16 auto flammability	As given in section 2	**Not highly flammable** **Not auto flammable up to the melting point**	n.r.	Y	1	142-001 A3.11/01 142-002 A3.11/02	[redacted]
3.12 Flash-point (IIA3.9)	EEC Directive 92/69 A 9	Not relevant	**Not relevant**	Not required, because the melting point is > 50 °C	n.r.	n.r.	n.r	[redacted]

Section A3 Physical and Chemical Properties of Active Substance

Subsection (Annex Point)	Method	Purity/ Specification	Results Give also data on test pressure, temperature, pH and concentration range if necessary	Remarks/ Justification	GLP (Y/N)	Reliability	Reference	Official use only
3.13 Surface tension (IIA3.10)	EEC Directive 92/69 A5	As given in section 2	**result:69.1 mN/m temperature: at 20 °C**	ring method concentration of test solution 158 ppm	Y	1	116-001 A3.13/01	[redacted]
3.14 Viscosity (-)				Not relevant IPBC is a solid and not a liquid				[redacted]
3.15 Explosive properties (IIA3.11)	Justification	-	**IPBC has no explosive properties**	Statement	Y	1	141-002 A3.15	[redacted]
3.16 Oxidizing properties (IIA3.12)	Justification	-	**IPBC has no oxidising properties**	Statement	Y	1	143-001 A3.15	[redacted]
3.17 Reactivity towards container material (IIA3.13)			**The test substance has to be stored in protected steel drums**					[redacted]

Section A3 RMS remarks to Physical and Chemical Properties of Active Substance

Subsection (Annex Point)	Method	Purity/ Specification	Results Give also data on test pressure, temperature, pH and concentration range if necessary	Remarks/ Justification	GLP (Y/N)	Reliability	Reference	Official use only
[redacted]								
[redacted]								
[redacted]	[redacted]						[redacted]	[redacted]
[redacted]	[redacted]						[redacted]	[redacted]
[redacted]	[redacted]						[redacted]	[redacted]
[redacted]								
[redacted]	[redacted]						[redacted]	[redacted]
[redacted]	[redacted]						[redacted]	[redacted]
[redacted]	[redacted]						[redacted]	[redacted]

Section A3 RMS remarks to Physical and Chemical Properties of Active Substance

Subsection (Annex Point)	Method	Purity/ Specification	Results Give also data on test pressure, temperature, pH and concentration range if necessary	Remarks/ Justification	GLP (Y/N)	Reliability	Reference	Official use only
[redacted]								
[redacted]	[redacted]						[redacted]	[redacted]
[redacted]	[redacted]						[redacted]	[redacted]
[redacted]								
[redacted]	[redacted]						[redacted]	[redacted]
	[redacted]						[redacted]	[redacted]
[redacted]	[redacted]						[redacted]	[redacted]
	[redacted]						[redacted]	[redacted]

Section A3 RMS remarks to Physical and Chemical Properties of Active Substance

Subsection (Annex Point)	Method	Purity/ Specification	Results Give also data on test pressure, temperature, pH and concentration range if necessary	Remarks/ Justification	GLP (Y/N)	Reliability	Reference	Official use only
								

Section A3 RMS remarks to Physical and Chemical Properties of Active Substance

Subsection (Annex Point)	Method	Purity/ Specification	Results Give also data on test pressure, temperature, pH and concentration range if necessary	Remarks/ Justification	GLP (Y/N)	Reliability	Reference	Official use only
[redacted]								
[redacted]	[redacted]						[redacted]	[redacted]
[redacted]	[redacted]						[redacted]	[redacted]

Section A3 RMS remarks to Physical and Chemical Properties of Active Substance

Subsection (Annex Point)	Method	Purity/ Specification	Results Give also data on test pressure, temperature, pH and concentration range if necessary	Remarks/ Justification	GLP (Y/N)	Reliability	Reference	Official use only
[redacted]								
[redacted]								
[redacted]								
[redacted]								
[redacted]								

Section A4.1 Analytical Method for the Detection and Identification

Annex Point IIA4.1 & 4.2
IIIA-IV.1

Official use only

1 REFERENCE

1.1 Reference

[redacted]

1.2 Data protection

[redacted]

1.2.1 Data owner

[redacted]

1.2.2 Companies with Letter of Access

[redacted]

1.2.3 Criteria for data protection

[redacted]

2.1 Guideline study

[redacted]

2.2 GLP

[redacted]

2.3 Deviations

[redacted]

3 MATERIALS AND METHODS

[redacted]

4 APPLICANT'S SUMMARY AND CONCLUSION

4.1 Materials and methods

[redacted]

4.2 Conclusion

[redacted]

4.2.1 Reliability

[redacted]

4.2.2 Deficiencies

[redacted]

	Evaluation by Competent Authorities
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]
Materials and methods	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	
	COMMENTS FROM ...
Date	*Give date of comments submitted*
Results and discussion	*Discuss additional relevant discrepancies referring to the (sub)heading numbers and to applicant's summary and conclusion.* *Discuss if deviating from view of rapporteur member state*
Conclusion	*Discuss if deviating from view of rapporteur member state*
Reliability	*Discuss if deviating from view of rapporteur member state*
Acceptability	*Discuss if deviating from view of rapporteur member state*
Remarks	

Section A4.1 Analytical Method for the Detection and Identification

Annex Point IIA4.1 & 4.2
IIIA-IV.1

Official use only

1 REFERENCE

1.1 Reference

[redacted]

1.2 Data protection

[redacted]

1.2.1 Data owner

[redacted]

1.2.2 Companies with Letter of Access

[redacted]

1.2.3 Criteria for data protection

[redacted]

2

2.1 Guideline study

[redacted]

2.2 GLP

[redacted]

2.3 Deviations

[redacted]

3 MATERIALS AND METHODS

[redacted]

4 APPLICANT'S SUMMARY AND CONCLUSION

4.1 Materials and methods

[redacted]

4.2 Conclusion

[redacted]

4.2.1 Reliability

[redacted]

4.2.2 Deficiencies

[redacted]

	Evaluation by Competent Authorities
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]
Materials and methods	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	
	COMMENTS FROM ...
Date	*Give date of comments submitted*
Results and discussion	*Discuss additional relevant discrepancies referring to the (sub)heading numbers and to applicant's summary and conclusion.* *Discuss if deviating from view of rapporteur member state*
Conclusion	*Discuss if deviating from view of rapporteur member state*
Reliability	*Discuss if deviating from view of rapporteur member state*
Acceptability	*Discuss if deviating from view of rapporteur member state*
Remarks	

Section A4.1 Analytical Methods for Detection and Identification

Annex Point IIA4.1/4.2 & IIIA-IV.1

Please refer to the "Confidential Data File" for data of the respective Task Force Members on analytical methods for the active substance and its impurities.

Section A4.2a/01

Annex Point IIA, IV.4.2 (a)

Analytical Method for the Detection and Identification of IPBC in soil

Official use only

1 REFERENCE

1.1	**Reference**	Bruckhausen, P. (2004): Development and validation of the residue analytical method for the determination of IPBC and its metabolite PBC in soil; RCC, Itingen Switzerland; Study No.: 851400; Doc. No. 434-001 (unpublished)
1.2	**Data protection**	[redacted]
1.2.1	Data owner	[redacted]
1.2.2	Companies with Letter of Access	[redacted]
1.2.3	Criteria for data protection	[redacted]

2

2.1	**Guideline study**	Yes; European Commission, Guidance Document on Residue Analytical Methods, SANCO/825/00 rev. 6, Jun. 20, 2000
2.2	**GLP**	Yes
2.3	**Deviations**	No

3 MATERIALS AND METHODS

3.1	**Preliminary treatment**	
3.1.1	Enrichment	Extraction with a mixture of acetone/water (3 + 2; v/v)
3.1.2	Cleanup	No further cleanup
3.2	**Detection**	
3.2.1	Separation method	Reversed phase chromatography on C 18 phase
3.2.2	Detector	MS/MS detection with positive electrospray ionisation.
3.2.3	Standard(s)	External calibration with IPBC and PBC calibration solutions
3.2.4	Interfering substance(s)	No interfering substances
3.3	**Linearity**	
3.3.1	Calibration range	IPBC 0.002 to 0.1 µg/mL PBC 0.002 to 0.1 µg/mL
3.3.2	Number of measurements	6 calibration standard solutions for each substance
3.3.3	Linearity	correlation coefficient r^2 IPBC 0.9999, PBC 0.9990

Section A4.2a/01 Analytical Method for the Detection and Identification of IPBC in soil

Annex Point IIA, IV.4.2 (a)

3.4	**Specifity: interfering substances**	The used method: HPLC-MS/MS is regarded as highly specific, an additional confirmatory method is not necessary. In control samples no interfering substances were observed.
3.5	**Recovery rates at different levels**	Fortification level 0.01 mg/kg IPBC mean (N=5) 78.5 % range: 71.1 - 92.4 % PBC mean (N=5) 80.9 % range: 73.1 - 88.5 % Fortification level 0.1 mg/kg IPBC mean (N=5) 82.5 % range: 74.6 - 92. 4 PBC mean (N=5) 83.9 % range: 69.7 - 96.1 %
3.5.1	Relative standard deviation	Fortification level 0.01 mg/kg IPBC 8.6 % (N=5) PBC 8.6 % (N=5) Fortification level 0.1 mg/kg IPBC 8.7 % (N=5) PBC 14.9 % (N=5)
3.6	**Limit of determination**	Limit of Detection (LOD) IPBC 0.004 mg/kg PBC 0.004 mg/kg Limit of Quantification (LOQ) IPBC 0.01 mg/kg PBC 0.01 mg/kg
3.7	**Precision**	
3.7.1	Repeatability	Fortification level 0.01 mg/kg IPBC 8.6 % (N=5) PBC 8.6 % (N=5) Fortification level 0.1 mg/kg IPBC 8.7 % (N=5) PBC 14.9 % (N=5)
3.7.2	Independent laboratory validation	Not necessary for a analytical method in soil

Section A4.2a/01

Annex Point IIA, IV.4.2 (a)

Analytical Method for the Detection and Identification of IPBC in soil

4 APPLICANT'S SUMMARY AND CONCLUSION

4.1 Materials and methods

In this method, residues of IPBC and PBC were extracted from soil with a mixture of acetone/water (3+2; v/v). The samples were shaken at 300 rpm for 15 min and centrifuged at 5000 rpm for 5 min. Analysis of the extract was done by HPLC using reversed-phase liquid chromatography and a 0.1 %(v/v) formic acid in water / 0.1 % (v/v) in methanol gradient. Detection was made with a MS/MS system and positive electrospray ionisation. Retention times were about 7.7 min for IPBC and about 5.8 min for PBC.

4.2 Conclusion

This method is suitable for use by regulatory agencies to detect IPBC and PBC in soil. The instrumentation required to perform the analysis method is available in most well equipped analytical laboratories. No toxic or hazardous reagents are required to prepare the samples, and all of the sample preparation equipment is commercially available. The method does not require the use of untreated commodity to correct for recoveries.

4.2.1 Reliability [redacted]

4.2.2 Deficiencies No

Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]
Materials and methods	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	
	COMMENTS FROM ...
Date	*Give date of comments submitted*
Results and discussion	*Discuss additional relevant discrepancies referring to the (sub)heading numbers and to applicant's summary and conclusion.* *Discuss if deviating from view of rapporteur member state*
Conclusion	*Discuss if deviating from view of rapporteur member state*
Reliability	*Discuss if deviating from view of rapporteur member state*
Acceptability	*Discuss if deviating from view of rapporteur member state*
Remarks	

Section A4.2b **Annex Point IIAIV.4.2(b)**	**Analytical Methods for the Detection and Identification of IPBC in air**	
	JUSTIFICATION FOR NON-SUBMISSION OF DATA	Official use only
Other existing data [ ] **Limited exposure [ ]**	**Technically not feasible [ ]** **Scientifically unjustified [ ]** **Other justification [X]**	
Detailed justification:	According to the TNsG on data requirements, an analytical method in air must be provided if the substance is volatile (i.e. if the vapour pressure is >= 0.01 Pa) or spayed, or occurrence in air is otherwise probable. [redacted]	
	Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted	
	EVALUATION BY RAPPORTEUR MEMBER STATE	
Date	[redacted]	
Evaluation of applicant's justification		
Conclusion	*Indicate whether applicant's justification is acceptable or not. If unacceptable because of the reasons discussed above, indicate which action will be required, e.g. submission of specific test/study data*	
Remarks		
	COMMENTS FROM OTHER MEMBER STATE *(specify)*	
Date	*Give date of comments submitted*	
Evaluation of applicant's justification	*Discuss if deviating from view of rapporteur member state*	
Conclusion	*Discuss if deviating from view of rapporteur member state*	
Remarks		

Section A4.2c/01 Analytical Method for the Detection and Identification of IPBC in water

Annex Point IIA, IV.4.2 (c)

Official use only

1 REFERENCE

1.1	**Reference**	Bruckhausen, P. (2004): Development and validation of the residue analytical method for the determination of IPBC and its metabolite PBC in drinking, ground and surface water; RCC, Itingen Switzerland; Study No.: 851401; Doc. No. 435-002 (unpublished)
1.2	**Data protection**	[redacted]
1.2.1	Data owner	[redacted]
1.2.2	Companies with Letter of Access	[redacted]
1.2.3	Criteria for data protection	[redacted]

2 GUIDELINES AND QUALITY ASSURANCE

2.1	**Guideline study**	Yes; European Commission, Guidance Document on Residue Analytical Methods, SANCO/825/00 rev. 6, Jun. 20, 2000
2.2	**GLP**	Yes
2.3	**Deviations**	No

3 MATERIALS AND METHODS

3.1	**Preliminary treatment**	
3.1.1	Enrichment	Solid-phase extraction cartridge (Isolute 101, Supelco)
3.1.2	Cleanup	No further cleanup
3.2	**Detection**	
3.2.1	Separation method	Reversed phase chromatography on C 18 phase
3.2.2	Detector	MS/MS detection with positive electrospray ionisation.
3.2.3	Standard(s)	External calibration with IPBC and PBC calibration solutions
3.2.4	Interfering substance(s)	No interfering substances
3.3	**Linearity**	
3.3.1	Calibration range	IPBC 0.001 to 0.1 µg/mL PBC 0.001 to 0.1 µg/mL
3.3.2	Number of measurements	7 calibration standard solutions for each substance
3.3.3	Linearity	correlation coefficient r^2 IPBC 0.9966, PBC 0.9978

Section A4.2c/01 Analytical Method for the Detection and Identification of IPBC in water

Annex Point IIA, IV.4.2 (c)

3.4	**Specifity: interfering substances**	The used method: HPLC-MS/MS is regarded as highly specific, an additional confirmatory method is not necessary. In control samples no interfering substances were observed.
3.5	**Recovery rates at different levels**	Please refer to table 4.2 -1
3.5.1	Relative standard deviation	Please refer to table 4.2 -1
3.6	**Limit of determination**	Limit of Detection (LOD) IPBC 0.02µg/L (for drinking, ground and surface water) PBC 0.02µg/L (for drinking, ground and surface water) Limit of Quantification (LOQ) IPBC 0.1µg/L (for drinking, ground and surface water) PBC 0.1µg/L (for drinking, ground and surface water)
3.7	**Precision**	
3.7.1	Repeatability	Please refer to table 4.2 -1
3.7.2	Independent laboratory validation	Not necessary for a analytical method in water

4 APPLICANT'S SUMMARY AND CONCLUSION

4.1	**Materials and methods**	In this method, residues of IPBC and PBC were extracted from water with a solid-phase extraction cartridge (Isolute 101, Supelco) and eluted with acetone. Analysis was done by HPLC using reversed-phase liquid chromatography and a 0.1 %(v/v) formic acid in water / 0.1 % (v/v) in methanol gradient. Detection was made with a MS/MS system and positive electrospray ionisation. Retention times were about 7.7 min for IPBC and about 5.9 min for PBC.
4.2	**Conclusion**	This method is suitable for use by regulatory agencies to detect IPBC and PBC in surface and drinking water. The instrumentation required to perform the analysis method is available in most well equipped analytical laboratories. No toxic or hazardous reagents are required to prepare the samples, and all of the sample preparation equipment is commercially available. The method does not require the use of untreated commodity to correct for recoveries.
4.2.1	Reliability	▮
4.2.2	Deficiencies	No

Table 4.2-1 Validation data for analytical methods for the determination of residues in water

Matrix	Test substance	Fortification level (µg/L)	Recovery rate (%)		RSD	N
			mean	range	(%)	
Drinking water	IPBC	0.1	84.5	74.7 – 90.7	7.9	5
	PBC	0.1	93.2	88.6 – 98.7	4.4	5
	IPBC	1.0	95.4	85.6 – 107.5	11.2	5
	PBC	1.0	92.0	84.1 – 101.9	8.2	5
Ground water	IPBC	0.1	98.7	93.0 – 104.0	4.8	5
	PBC	0.1	97.7	85.5 – 110.3	12.3	5
	IPBC	1.0	101.3	94.6 – 113.6	7.4	5
	PBC	1.0	90.3	80.3 – 105.8	11.9	5
Surface water	IPBC	0.1	93.7	76.2 – 107.4	13.7	5
	PBC	0.1	98.7	84.9 – 112.9	10.3	5
	IPBC	1.0	96.0	76.7 – 107.0	12.5	5
	PBC	1.0	86.1	82.1 – 95.2	6.2	5

Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]
Materials and methods	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	
	COMMENTS FROM ...
Date	*Give date of comments submitted*
Results and discussion	*Discuss additional relevant discrepancies referring to the (sub)heading numbers and to applicant's summary and conclusion.* *Discuss if deviating from view of rapporteur member state*
Conclusion	*Discuss if deviating from view of rapporteur member state*
Reliability	*Discuss if deviating from view of rapporteur member state*
Acceptability	*Discuss if deviating from view of rapporteur member state*
Remarks	

Section A4.2d Annex Point IIAIV.4.2 (d)	Analytical Methods for Detection and Identification of IPBC in animal and human body fluids and tissues	
	JUSTIFICATION FOR NON-SUBMISSION OF DATA	Official use only
Other existing data [ ]	**Technically not feasible** [ ] **Scientifically unjustified** [ ]	
Limited exposure [ ]	**Other justification** [X]	
Detailed justification:	According to the TNsG on data requirements, an analytical method in animal and human body fluids and tissues must be provided if the substance is classified as toxic or highly toxic. [redacted]	
	Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted	
	EVALUATION BY RAPPORTEUR MEMBER STATE	
Date	[redacted]	
Evaluation of applicant's justification	[redacted]	
Conclusion	[redacted]	
Remarks		

Section A4.2e **Annex Point IIA,IV.4.2 (e)**	**Analytical Methods for Detection and Identification of IPBC in food and feeding stuffs and other products where relevant**	
	JUSTIFICATION FOR NON-SUBMISSION OF DATA	Official use only
Other existing data [ ]	**Technically not feasible** [ ] **Scientifically unjustified** [ ]	
Limited exposure [ ]	**Other justification** [X]	
Detailed justification:	According to the TNsG on data requirements, an analytical method in food or feeding stuffs or other products must be provided if the substance or the material treated with it is to be used in a manner which may cause contact with food or feeding stuffs, or intended to be placed on , in, or near soils in agricultural or horticultural use. [redacted]	
	Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted	
	EVALUATION BY RAPPORTEUR MEMBER STATE	
Date	*Give date of action*	
Evaluation of applicant's justification	*Discuss applicant's justification and, if applicable, deviating view*	
Conclusion	*Indicate whether applicant's justification is acceptable or not. If unacceptable because of the reasons discussed above, indicate which action will be required, e.g. submission of specific test/study data*	
Remarks		
	COMMENTS FROM OTHER MEMBER STATE *(specify)*	
Date	*Give date of comments submitted*	
Evaluation of applicant's justification	*Discuss if deviating from view of rapporteur member state*	
Conclusion	*Discuss if deviating from view of rapporteur member state*	
Remarks		

Section A5 Effectiveness against target organisms and intended uses: Active substance IPBC

Subsection (Annex Point)			Official use only
5.1	**Function (IIA5.1)**	Fungicide	
5.2	**Organism(s) to be controlled and products, organisms or objects to be protected (IIA5.2)**	-	
5.2.1	**Organism(s) to be controlled (IIA5.2)**	The following organisms are controlled (PT8): (a) Wood rotting (destroying) fungi (basidiomycetes) (b) Wood disfiguring (discolouring) fungi (blue stain, mould and sapstain)	
5.2.2	**Products, organisms or objects to be protected (IIA5.2)**	PT8: IPBC is a fungicide for treatment of wood for above-ground use (Hazard classes 2 and 3).	
5.3	**Effects on target organisms, and likely concentration at which the active substance will be used (IIA5.3)**	-	
5.3.1	**Effects on target organisms (IIA5.3)**	Depending on the concentrations applied, IPBC exerts fungitoxic or fungistatic effects on a broad range of wood-damaging fungi. Basic data on the efficacy of IPBC against wood-destroying fungi (basidiomycetes) are summarised in the table at the end of the chapter. The following minimum inhibitory concentrations (ppm IPBC) were determined (Brisco et al. (1990): Microbial tolerance and biodetoxicification of organic and organometallic biocides, Twenty-first Annual Meeting of the International Research Group on Wood Preservation, IRG Secretariat, Box 5607, 114 86 Stockholm, Sweden, Doc. No. 392-011): Trichoderma harzianum: 12 ppm Aureobasidium pullulans: 7 ppm Philophora fastigiata: 10 ppm Coniophora putanea: 1 ppm Chaetomium globosum: 6 ppm Coriolus versicolor: 0.5 ppm	

Section A5 Effectiveness against target organisms and intended uses: Active substance IPBC

5.3.2 Likely concentrations at which the A.S. will be used (IIA5.3)

IPBC based wood preservation products (PT8) contain in most cases other fungicidal active substances like propiconazole, tebuconazole, or carbendazime. Many products also contain insecticides like permethrine, cypermethrine, or others. Depending on the use/treatment process, the level of protection required, and the nature and concentration of the other active ingredients present in the respective formulated products, the IPBC concentrations vary considerably in the treatment solutions.

IPBC based wood preservation products are employed for the following uses at the IPBC concentrations indicated:

(a) Industrial uses (preventive uses):

- Double vacuum treatment
- Supercritical CO_2:
- Vacuum pressure treatment
- Automated spraying
- Flow coat
- Dipping

(b) professional

- Brushing
- Spraying and brushing
- Injection in holes

(c) amateur uses

- Brushing
- Spraying and brushing

Most uses listed above are preventive. Curative (remedial) applications are also possible (specifically stated in above list where applicable).

A more detailed compilation of uses, uses rates and concentrations is provided in Document IIB Chapter 8.

Section A5 Effectiveness against target organisms and intended uses: Active substance IPBC

5.4	**Mode of action (including time delay) (IIA5.4)**	-
5.4.1	**Mode of action**	IPBC has a Carbamate structure. The target sites of Carbamates in fungi are cell membrane permeability and fatty acids (according to the information provided by FRAC (Fungicide Resistance Action Committee)on its website http://www.frac.info/publications/frac_list01.html
5.4.2	**Time delay**	Not a relevant point for a wood preservation substance
5.5	**Field of use envisaged (IIA5.5)**	Include code(s) and term(s)
	MG02: Preservatives	IPBC is used in products of the following Product Types: PT06: In-can preservatives PT07: Film preservatives PT08: Wood preservatives PT09: Fibre, leather, rubber and polymerised materials preservatives PT10: Masonry preservatives PT13: Metalworking preservatives In the present dossier, only the use of IPBC for wood preservation is addressed. **Fields of use envisaged:** Wood preservative, indoor use, Hazard class 2 Wood preservative, outdoor use; Hazard classes 2 and 3
	Further specification	A detailed listing of the uses in PT8 (wood preservation) is provided under point 5.3.2 and in Document IIB Chapter 8.
5.6	**User (IIA5.6)**	Please refer to Document IIB, Chapters 8.1 and 8.2
	Industrial	See above: Doc. IIIA, Section A5.3.2
	Professional	See above: Doc. IIIA, Section A5.3.2
	General public	See above: Doc. IIIA, Section A5.3.2
5.7	**Information on the occurrence or possible occurrence of the development of resistance and appropriate management strategies (IIA5.7)**	
5.7.1	**Development of resistance**	IPBC has a Carbamate structure. The target sites of Carbamates in fungi are cell membrane permeability and fatty acids (according to the information provided by FRAC (Fungicide Resistance Action Committee)on its website (see above: Section 5.4.1).

Section A5 Effectiveness against target organisms and intended uses: Active substance IPBC

The risk of resistance formation against Carbamate fungicides is regarded to be low to medium by FRAC (Fungicide Resistance Action Committee. This applies to the use of Carbamate fungicides in agriculture, where yearly applications to the same fields are possible (even more than one application per season is possible).

With regard to the use of Cabamates in wood preservation, resistance formation constitutes an even smaller problem: The number of treatments to a wooden structures is generally low (in many cases, only one application is made per lifetime of timber structures), resulting in a low selection pressure.

5.7.2 Management strategies

IPBC is mostly used in combination products containing other active ingredient like propiconazole, tebuconazole, or carbendazim. These active substances have different modes of action (propiconazole/ tebuconazole: inhibition of sterol biosynthesis; carbendazim: inhibition of mitosis). For this reason, the low risk of resistance build-up is further reduced.

5.8 Likely tonnage to be placed on the market per year (IIA5.8)

Confidential information: Please refer to the "Confidential-Data file".

Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]
Materials and methods	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	[redacted]
	COMMENTS FROM ...
Date	Give date of comments submitted
Results and discussion	Discuss additional relevant discrepancies referring to the (sub)heading numbers and to applicant's summary and conclusion. Discuss if deviating from view of rapporteur member state
Conclusion	Discuss if deviating from view of rapporteur member state
Reliability	Discuss if deviating from view of rapporteur member state
Acceptability	Discuss if deviating from view of rapporteur member state
Remarks	

Table 5.3-1: Summary table of experimental data on the effectiveness of the active substance against target organisms at different fields of use envisaged, where applicable

Function	Field of use envisaged	Test substance	Test organism(s)	Test method/ Wood species tested	Test results: Toxic value (kg/m^3)		Reference*)
Function as given in section 5.1	PT concerned	1. IPBC applied as formulated product 2. IPBC not formulated	Fungal species	Test system and wood species	unleached	leached	Only author(s) and year of publication/ report; full bibliographic data in footnote
Fungicide	PT8	1	Coniophora putanea	EN-113/ Pine	0.2 – 0.4	0.3 – 0.5	Hansen, John, 1984
Fungicide	PT8	1	Poria monticola	EN-113/ Pine	0.13 – 0.26	0.2 – 0.3	dito
Fungicide	PT8	1	Lentinus lepideus	EN-113/ Pine	0.27 – 0.33	0.4 – 0.8	dito
Fungicide	PT8	1	Lenzites trabea	EN-113/ Pine	0.09 – 0.12	Not determined	dito
Fungicide	PT8	1	Polystictus versicolor	EN-113/ Pine	0.3 – 0.4	0.4 – 0.8	dito
Fungicide	PT8	2	Gloeophyllum trabeum	ASTM/ Pine	0.4 – 0.7	1.5 – 3.0	dito
Fungicide	PT8	1	Gloeophyllum trabeum	ASTM/ Pine	0.2 – 0.4	0.62 – 1.1	dito
Fungicide	PT8	2	Poria placenta	ASTM/ Aspen	0.19 – 0.38	Not determined	dito
Fungicide	PT8	2	Poria placenta	ASTM/ Pine	0.06 – 0.38	Not determined	dito
Fungicide	PT8	2	Polyporus versicolor	ASTM/ Aspen	0.38 – 0.75	Not determined	dito
Fungicide	PT8	2	Polyporus tulipiferae	ASTM/ Aspen	0.19 – 0.38	Not determined	dito
Fungicide	PT8	2	Poria vaillantii	ASTM/ Pine	<0.19	Not determined	dito

*)References:

Hansen (1984), IPBC – A new fungicide for wood protection, Fifteenth Annual Meeting of the International Research Group on Wood Preservation, IRG Secretariat, Drottning Kristinas vag 47c, 114 28 Stockholm, Sweden, Doc. No. 392-002

Section A6.1.1/01 Acute Toxicity

Annex Point IIA, VI.6.1.1 **Oral, Rat, LD_{50}**

[redacted]

			Official use only
		1 REFERENCE	
1.1	**Reference**	[redacted] (2000): Preventol MP 100 Acute Oral Toxicity Study in Male and Female Wistar Rats; [redacted] 17.11.2000 [redacted]	[redacted]
1.2	**Data protection**	[redacted]	
1.2.1	Data owner	[redacted]	
1.2.2	Companies with letter of access	[redacted]	
1.2.3	Criteria for data protection	[redacted]	
		2 GUIDELINES AND QUALITY ASSURANCE	
2.1	**Guideline study**	[redacted] OECD guideline 423 (adopted 22nd March, 1996) and Annex IVB, Part B.1 tris to Directive 67/548/EEC, as amended by Directive 96/54/EEC (30.06.1996) and followed, in principle, OPPTS 870.1100	[redacted]
2.2	**GLP**	[redacted]	
2.3	**Deviations**	None	
		3 MATERIALS AND METHODS	
3.1	**Test material**	[redacted]	
3.1.1	Lot/Batch number	[redacted]	
3.1.2	Specification	As given in section 2	
3.1.3	Purity	[redacted]	
3.1.4	Description	[redacted]	
3.1.5	Stability	[redacted]	

Section A6.1.1/01 Acute Toxicity

Annex Point IIA, VI.6.1.1 Oral, Rat, LD_{50}

3.2	**Test Animals**	
3.2.1	Species	Rat
3.2.2	Strain	Wistar (HsdCpd:WU)
3.2.3	Source	[redacted]
3.2.4	Sex	Male, female
3.2.5	Age/weight at study initiation	[redacted]
3.2.6	Number of animals per group	[redacted] *
3.2.7	Control animals	[redacted]
3.3	**Administration/ Exposure**	Oral
3.3.1	Post-exposure period	[redacted]
3.3.2	Type	Gavage
3.3.3	Concentration	[redacted]
3.3.4	Vehicle	[redacted]
3.3.5	Concentration in vehicle	[redacted]
3.3.6	Total volume applied	[redacted]
3.3.7	Controls	[redacted]
3.4	**Examinations**	[redacted]
3.5	**Method of determination of LD_{50}**	[redacted]
3.6	**Further remarks**	None

4 RESULTS AND DISCUSSION

4.1	**Clinical signs**	[redacted]
4.2	**Pathology**	[redacted]
4.3	**Other**	[redacted]
4.4	**LD_{50}**	300 to 500 mg/kg bw

Section A6.1.1/01 Acute Toxicity

Annex Point IIA, VI.6.1.1 **Oral, Rat, LD_{50}**

5 APPLICANT'S SUMMARY AND CONCLUSION

This study was performed to assess the acute oral toxicity of IPBC to the rat (OECD guideline 423).

5.1 Materials and methods

[redacted]

5.2 Results and discussion

[redacted]

5.3 Conclusion

LD_{50} 300 - 500 mg/kg bw

5.3.1 Reliability [redacted]

5.3.2 Deficiencies [redacted]

Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]
Materials and Methods	[redacted]
Results and discussion	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	

Section A6.1.1/01 Acute Toxicity

Annex Point IIA, VI.6.1.1 Oral, Rat, LD_{50}

[redacted]

[redacted]				

Section A6.1.2/01 Acute Toxicity
Annex Point IIA, VI.6.1.2 Dermal, Rat, Limit test

[redacted]

			Official use only
		1 REFERENCE	
1.1	**Reference**	[redacted] (2000): Preventol MP 100 – Acute Dermal Toxicity Study in Male and Female Wistar Rats; [redacted] 17.11.2000	[redacted]
1.2	**Data protection**	[redacted]	
1.2.1	Data owner	[redacted]	
1.2.2	Companies with letter of access	[redacted]	
1.2.3	Criteria for data protection	[redacted]	
		2 GUIDELINES AND QUALITY ASSURANCE	
2.1	**Guideline study**	[redacted] OECD guideline 402 (adopted 24.02.1987) and followed, in principle, OPPTS 870.1200 and Annex V, Part B.3. to Directive 67/548/EEC (27.06.1967) as amended by Directive 92/69/EEC (31.07.1992)	[redacted]
2.2	**GLP**	[redacted]	
2.3	**Deviations**	None	
		3 MATERIALS AND METHODS	
3.1	**Test material**	[redacted]	
3.1.1	Lot/Batch number	[redacted]	
3.1.2	Specification	As given in section 2	
3.1.3	Purity	[redacted]	
3.1.4	Description	[redacted]	
3.1.5	Stability	[redacted]	
3.2	**Test Animals**		
3.2.1	Species	Rat	
3.2.2	Strain	Wistar (HsdCpd:WU)	
3.2.3	Source	[redacted]	
3.2.4	Sex	male, female	
3.2.5	Age/weight at study initiation	[redacted]	

Section A6.1.2/01 Acute Toxicity

Annex Point IIA, VI.6.1.2 **Dermal, Rat, Limit test**

3.2.6	Number of animals per group	[redacted]
3.2.7	Control animals	[redacted]
3.3	**Administration/ Exposure**	dermal
3.3.1	Post-exposure period	[redacted]
3.3.2	Area covered	[redacted]
3.3.3	Occlusion	[redacted]
3.3.4	Vehicle	[redacted]
3.3.5	Concentration in vehicle	[redacted]
3.3.6	Total volume applied	[redacted]
3.3.7	Duration of exposure	[redacted]
3.3.8	Removal of test substance	[redacted]
3.4	**Examinations**	[redacted]
3.5	**Method of determination of LD_{50}**	[redacted]
3.6	**Further remarks**	None
		4 RESULTS AND DISCUSSION
4.1	**Clinical signs**	[redacted]
4.2	**Pathology**	[redacted]
4.3	**Other**	[redacted]
4.4	**LD_{50}**	No lethal effect at maximal dose LD_{50}: > 2000 mg/kg bw

Section A6.1.2/01 Acute Toxicity

Annex Point IIA, VI.6.1.2 Dermal, Rat, Limit test

5 APPLICANT'S SUMMARY AND CONCLUSION

5.1 Materials and methods

This study was performed to assess the acute dermal toxicity of IPBC to rat (OECD guideline 402).

[redacted]

5.2 Results and discussion

[redacted]

5.3 Conclusion

LD_{50}: > 2000 mg/kg bw

5.3.1 Reliability [redacted]

5.3.2 Deficiencies [redacted]

Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]
Materials and Methods	[redacted]
Results and discussion	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	

[redacted]

[redacted]

Section A6.1.3/01 Acute Toxicity

Annex Point IIA, VI.6.1.3 Inhalation, Rat, Limit test

[redacted]

			Official use only
		1 REFERENCE	
1.1	**Reference**	[redacted] 1985): Acute Inhalation Limit Test in Rats 3-Iodo-2-propynyl butyl carbamate [redacted] 14.05.1985 [redacted]	[redacted]
1.2	**Data protection**	[redacted]	
1.2.1	Data owner	[redacted]	
1.2.2	Companies with letter of access	[redacted]	
1.2.3	Criteria for data protection	[redacted]	
		2 GUIDELINES AND QUALITY ASSURANCE	
2.1	**Guideline study**	[redacted] OECD 403 guideline (adopted 1981)	[redacted]
2.2	**GLP**	[redacted]	
2.3	**Deviations**	Yes The actual test substance concentration was calculated and not determined by analysis.	
		3 MATERIALS AND METHODS	
3.1	**Test material**	[redacted]	
3.1.1	Lot/Batch number	[redacted]	
3.1.2	Specification	As given in section 2	
3.1.3	Purity	[redacted]	
3.1.4	Description	[redacted]	
3.1.5	Stability	[redacted]	

Section A6.1.3/01 Acute Toxicity

Annex Point IIA, VI.6.1.3 Inhalation, Rat, Limit test

3.2	**Test Animals**	
3.2.1	Species	Rat
3.2.2	Strain	Sprague-Dawley
3.2.3	Source	[redacted]
3.2.4	Sex	male, female
3.2.5	Age/weight at study initiation	[redacted]
3.2.6	Number of animals per group	[redacted]
3.2.7	Control animals	[redacted]
3.3	**Administration/ Exposure**	Inhalation
3.3.1	Post-exposure period	[redacted]
3.3.2	Concentrations	[redacted]
3.3.3	Particle size	[redacted] *
3.3.4	Type or preparation of particles	[redacted]
3.3.5	Type of exposure	[redacted]
3.3.6	Vehicle	[redacted]
3.3.7	Concentration in vehicle	[redacted]
3.3.8	Duration of exposure	[redacted]
3.3.9	Controls	[redacted]
3.4	**Examinations**	[redacted]
3.5	**Method of determination of LC_{50}**	[redacted]
3.6	**Further remarks**	None

Section A6.1.3/01 Acute Toxicity

Annex Point IIA, VI.6.1.3 Inhalation, Rat, Limit test

4 RESULTS AND DISCUSSION

4.1 Clinical signs

[redacted]

4.2 Pathology

[redacted]

4.3 Other

[redacted]

4.4 LC_{50}

LC_{50} > 6.89 mg/L for males and females

[redacted]

5 APPLICANT'S SUMMARY AND CONCLUSION

5.1 Materials and methods

This study was performed to assess the acute toxicity of IPBC via the inhalation route (OECD guidelines 403).

[redacted]

5.2 Results and discussion

[redacted]

5.3 Conclusion

LC_{50} > 6.89 mg/L

5.3.1 Reliability [redacted]

5.3.2 Deficiencies [redacted]

Section A6.1.3/01 Acute Toxicity

Annex Point IIA, VI.6.1.3 Inhalation, Rat, Limit test

Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]
Materials and Methods	[redacted]
Results and discussion	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	[redacted]

Section A6.1.3/01 Acute Toxicity

Annex Point IIA, VI.6.1.3 **Inhalation, Rat, Limit test**

[redacted]

[redacted]				
[redacted]				

Section A6.1.3/02 Acute Toxicity

Annex Point IIA, VI.6.1.3 Inhalation, Rat, LC_{50}

			Official use only
		1 REFERENCE	
1.1	**Reference**	[redacted] (1990): (Troysan Polyphase P-100) – Acute Inhalation Toxicity Study in the Rat; [redacted] 08.11.1990 [redacted]	[redacted]
1.2	**Data protection**	[redacted]	
1.2.1	Data owner	[redacted]	
1.2.2	Companies with letter of access	[redacted]	
1.2.3	Criteria for data protection	[redacted]	
		2 GUIDELINES AND QUALITY ASSURANCE	
2.1	**Guideline study**	[redacted] US EPA guidelines, Subdivision F: Hazard Evaluation: Human and Domestic Animals; Section 81-3 "Acute Inhalation Toxicity Study", November 1984 which is comparable to OECD 403.	
2.2	**GLP**	[redacted]	
2.3	**Deviations**	Yes, the chamber temperatures were occasionally below the required range of 20 to 24°C. On occasion, the relative humidity exceeded the desired range of 40 to 60%. However, this was not considered to have affected the outcome of the study	
		3 MATERIALS AND METHODS	
3.1	**Test material A**	[redacted]	
3.1.1	Lot/Batch number	[redacted]	
3.1.2	Specification	As given in section 2	
3.1.2.1	Description	[redacted]	
3.1.2.2	Purity	[redacted]	
3.1.2.3	Stability	[redacted]	
3.2	**Test material B**	[redacted]	
3.2.1	Lot/Batch number	[redacted]	*
3.2.2	Specification	Not applicable	
3.2.2.1	Description	[redacted]	

Section A6.1.3/02 Acute Toxicity

Annex Point IIA, VI.6.1.3 Inhalation, Rat, LC_{50}

3.2.2.2	Purity	[redacted]
3.2.2.3	Stability	[redacted]
3.3	**Test Animals**	
3.3.1	Species	Rat
3.3.2	Strain	Sprague-Dawley CD®
3.3.3	Source	[redacted]
3.3.4	Sex	male, female
3.3.5	Age/weight at study initiation	[redacted]
3.3.6	Number of animals per group	[redacted]
3.3.7	Control animals	[redacted]
3.4	**Administration/ Exposure**	Inhalation
3.4.1	Post-exposure period	[redacted]
3.4.2	Concentrations	[redacted]

Section A6.1.3/02 Acute Toxicity

Annex Point IIA, VI.6.1.3 Inhalation, Rat, LC_{50}

3.4.3	Particle size	[redacted]
3.4.4	Type or preparation of particles	[redacted]
3.4.5	Type of exposure	whole body
3.4.6	Vehicle	[redacted]
3.4.7	Concentration in vehicle	[redacted]
3.4.8	Duration of exposure	[redacted]
3.4.9	Controls	[redacted]
3.5	**Examinations**	[redacted]
3.6	**Method of determination of LC_{50}**	[redacted]
3.7	**Further remarks**	[redacted]

Section A6.1.3/02 Acute Toxicity

Annex Point IIA, VI.6.1.3 Inhalation, Rat, LC_{50}

4 RESULTS AND DISCUSSION

4.1 Clinical signs

[redacted]

4.2 Pathology

[redacted]

4.3 Other

[redacted]

4.4 LC_{50}

dust:
0.68 mg/L for combined sexes
0.67 mg/L for males
0.67 mg/L for females

liquid aerosol:
0.78 mg formulation/L for combined sexes
0.63 mg formulation /L for males
0.99 mg formulation /L for females

Section A6.1.3/02 Acute Toxicity

Annex Point IIA, VI.6.1.3 Inhalation, Rat, LC_{50}

5 APPLICANT'S SUMMARY AND CONCLUSION

5.1 Materials and methods

This study was performed to assess the acute toxicity of IPBC via the inhalation route (US-EPA guideline 81-3).

[redacted]

5.2 Results and discussion

[redacted]

5.3 Conclusion

Comb. Sexes:

LC_{50}: 0.68 mg/L dust
LC_{50}: 0.78 mg formulation /L liquid aerosol

5.3.1 Reliability [redacted]

5.3.2 Deficiencies [redacted]

Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]
Materials and Methods	[redacted]
	[redacted]
Results and discussion	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	

Section A6.1.3/02 Acute Toxicity

Annex Point IIA, VI.6.1.3 **Inhalation, Rat, LC_{50}**

[redacted]

[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]

[redacted]

[redacted]					
[redacted]					
[redacted]					
[redacted]					
[redacted]					
[redacted]					
[redacted]					
[redacted]					
[redacted]					

Section A6.1.4/01 Acute Toxicity

Annex Point IIA, VI.6.1.4 Skin Irritation, Rabbit

[redacted]

			Official use only
		1 REFERENCE	
1.1	**Reference**	[redacted] (2000): Acute Skin Irritation Test (Patch Test) of Preventol MP 100 in Rabbits [redacted] 27.10.2000 [redacted]	[redacted]
1.2	**Data protection**	[redacted]	
1.2.1	Data owner	[redacted]	
1.2.2	Companies with letter of access	[redacted]	
1.2.3	Criteria for data protection	[redacted]	
		2 GUIDELINES AND QUALITY ASSURANCE	
2.1	**Guideline study**	[redacted] OECD guideline 404 (17.07.1992) and EC guideline B.4. (29.12.1992)	
2.2	**GLP**	[redacted]	
2.3	**Deviations**	[redacted]	
		3 MATERIALS AND METHODS	
3.1	**Test material**	[redacted]	
3.1.1	Lot/Batch number	[redacted]	
3.1.2	Specification	As given in section 2	
3.1.3	Purity	[redacted]	
3.1.4	Description	[redacted]	
3.1.5	Stability	[redacted]	
3.2	**Test Animals**		
3.2.1	Species	Rabbit	
3.2.2	Strain	Himalayan	
3.2.3	Source	[redacted]	
3.2.4	Sex	Male	
3.2.5	Age/weight at study initiation	[redacted]	

Section A6.1.4/01 Acute Toxicity

Annex Point IIA, VI.6.1.4 Skin Irritation, Rabbit

3.2.6	Number of animals per group	[redacted]
3.2.7	Control animals	[redacted]
3.3	**Administration/ Exposure**	Dermal
3.3.1	Application	
3.3.1.1	Preparation of test substance	[redacted]
3.3.1.2	Test site and Preparation of Test Site	[redacted]
3.3.2	Occlusion	[redacted]
3.3.3	Vehicle	[redacted]
3.3.4	Concentration in vehicle	[redacted]
3.3.5	Total volume applied	[redacted]
3.3.6	Removal of test substance	[redacted]
3.3.7	Duration of exposure	[redacted]
3.3.8	Post-exposure period	[redacted]
3.3.9	Controls	[redacted]
3.4	**Examinations**	
3.4.1	Clinical signs	[redacted]
3.4.2	Dermal examination	[redacted]
3.4.2.1	scoring system	[redacted]
3.4.2.2	Examination time points	[redacted]
3.5	**Further remarks**	None

Section A6.1.4/01 Acute Toxicity
Annex Point IIA, VI.6.1.4 Skin Irritation, Rabbit

4 RESULTS AND DISCUSSION

4.1	**Average score**	
4.1.1	Erythema	Average scores for all animals at 24 and 48 h were 1. After 72 h no erythema were observed. *
4.1.2	Oedema	At any time point no oedema was detected
4.2	**Reversibility**	Yes, erythema were reversible in animal 2 after 48 h, in animal 1 after 72 h and in animal 3 after 5 days.
4.3	**Other examinations**	There were no systemic intolerance reactions.
4.4	**Overall result**	IPBC is non-irritating to skin.

5 APPLICANT'S SUMMARY AND CONCLUSION

5.1	**Materials and methods**	This study was performed to assess acute dermal irritation effects of Preventol MP 100 (3-Iodo-2-propynyl-n-butyl carbamate) in rabbits (OECD guideline 404). [redacted]
5.2	**Results and discussion**	[redacted]
5.3	**Conclusion**	non-irritating to skin
5.3.1	Reliability	[redacted]
5.3.2	Deficiencies	[redacted]

Evaluation by Competent Authorities

Use separate "evaluation boxes" to provide transparency as to the comments and views submitted

EVALUATION BY RAPPORTEUR MEMBER STATE

Date	[redacted]
Materials and Methods	[redacted]
Results and discussion	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	[redacted]

Section A6.1.4/01 Acute Toxicity

Annex Point IIA, VI.6.1.4 **Skin Irritation, Rabbit**

[redacted]

[redacted]			

Section 6.1.4/02 Acute Toxicity

Annex Point IIA, VI.6.1.4 Eye Irritation, Rabbit

[redacted]

			Official use only
		1 REFERENCE	
1.1	**Reference**	[redacted] (1998): Primary Eye Irritation – IPEX 1000; [redacted] 23.06.1998;	[redacted]
1.2	**Data protection**	[redacted]	
1.2.1	Data owner	[redacted]	
1.2.2	Companies with letter of access	[redacted]	
1.2.3	Criteria for data protection	[redacted]	
		2 GUIDELINES AND QUALITY ASSURANCE	
2.1	**Guideline study**	[redacted] 40 CFR 158, Guideline 81-4 and comparable to OECD guideline 405	
2.2	**GLP**	[redacted]	
2.3	**Deviations**	[redacted]	
		3 MATERIALS AND METHODS	
3.1	**Test material**	[redacted]	
3.1.1	Lot/Batch number	[redacted]	
3.1.2	Specification	As given in section 2	
3.1.3	Purity	[redacted]	
3.1.4	Description	[redacted]	
3.1.5	Stability	[redacted]	
3.2	**Test Animals**		
3.2.1	Species	Rabbit	
3.2.2	Strain	New Zealand Albino	
3.2.3	Source	[redacted]	
3.2.4	Sex	male, female	
3.2.5	Age/weight at study initiation	not indicated	
3.2.6	Number of animals per group	[redacted]	
3.2.7	Control animals	[redacted]	

Section 6.1.4/02 Acute Toxicity

Annex Point IIA, VI.6.1.4 Eye Irritation, Rabbit

3.3	**Administration/ Exposure**	
3.3.1	Preparation of test substance	[redacted]
3.3.2	Amount of active substance instilled	[redacted]
3.3.3	Exposure period	[redacted]
3.3.4	Post-exposure period	[redacted]
3.4	**Examinations**	
3.4.1	Ophthalmoscopic examination	[redacted]
3.4.1.1	Scoring system	[redacted]
3.4.1.2	Examination time points	[redacted]
3.4.2	Other investigations	[redacted]
3.5	**Further remarks**	[redacted]
		4 RESULTS AND DISCUSSION
4.1	**Clinical signs**	There were no systemic intolerance reactions
4.2	**Average score**	
4.2.1	Cornea	Average score of all animals at 24, 48, and 72 h was 1.67.
4.2.2	Iris	Average score of all animals at 24, 48, and 72 h was 1.17.
4.2.3	Conjunctiva	
4.2.3.1	Redness	Average score of all animals at 24, 48, and 72 h was 2.17.
4.2.3.2	Chemosis	Average score of all animals at 24, 48, and 72 h was 4.
4.3	**Reversibility**	The observed effects persisted during the 7 day period of investigation.
4.4	**Other**	none
4.5	**Overall result**	IPBC represent a risk for serious damage to eyes
		5 APPLICANT'S SUMMARY AND CONCLUSION
5.1	**Materials and methods**	This study was performed to assess acute eye irritation effects of IPBC in rabbits.
		[redacted]
5.2	**Results and discussion**	[redacted]
5.3	**Conclusion**	Severely irritant to the eye.
5.3.1	Reliability	[redacted]
5.3.2	Deficiencies	[redacted]

Section 6.1.4/02 Acute Toxicity

Annex Point IIA, VI.6.1.4 Eye Irritation, Rabbit

	Evaluation by Competent Authorities
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]
Materials and Methods	[redacted]
Results and discussion	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	

[redacted]

[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]			
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]				

Section A6.1.5/01 Skin sensitisation

Annex Point IIA, VI.6.1.5 Buehler method

[redacted]

			Official use only
		1 REFERENCE	
1.1	**Reference**	[redacted] (1998): Dermal Sensitisation Test – Buehler Method; [redacted] 23.06.1998	[redacted]
1.2	**Data protection**	[redacted]	
1.2.1	Data owner	[redacted]	
1.2.2	Companies with letter of access	[redacted]	
1.2.3	Criteria for data protection	[redacted]	
		2 GUIDELINES AND QUALITY ASSURANCE	
2.1	**Guideline study**	[redacted] US EPA, guideline 81-6 and OECD 406	[redacted]
2.2	**GLP**	[redacted]	
2.3	**Deviations**	[redacted]	*
		3 MATERIALS AND METHODS	
3.1	**Test material**	[redacted]	
3.1.1	Lot/Batch number	[redacted]	
3.1.2	Specification	As given in section 2	
3.1.3	Purity	[redacted]	
3.1.4	Description	[redacted]	
3.1.5	Stability	[redacted]	
3.1.5.1	Preparation of test substance for application	[redacted]	
3.1.5.2	Pretest performed	[redacted]	

Section A6.1.5/01 Skin sensitisation

Annex Point IIA, VI.6.1.5 Buehler method

	on irritant effects	
3.2	**Test Animals**	
3.2.1	Species	Guinea pigs
3.2.2	Strain	Hartley albino
3.2.3	Source	[redacted]
3.2.4	Sex	male
3.2.5	Age/weight at study initiation	[redacted]
3.2.6	Number of animals per group	[redacted]
3.2.7	Control animals	[redacted]
3.3	**Administration/ Exposure**	Non-adjuvant
3.3.1	Induction schedule	[redacted]
3.3.2	Way of Induction	topical
3.3.3	Concentrations used for induction	[redacted]
3.3.4	Challenge schedule	[redacted]
3.3.5	Concentrations used for challenge	[redacted]
3.3.6	Re-challenge	[redacted]
3.3.7	Scoring schedule	[redacted] *
3.3.8	Removal of the test substance	[redacted]
3.3.9	Positive control substance	[redacted]

Section A6.1.5/01 Skin sensitisation

Annex Point IIA, VI.6.1.5 Buehler method

3.4	**Examinations**	
3.4.1	Pilot study	[redacted]
3.5	**Further remarks**	None

4 RESULTS AND DISCUSSION

4.1	**Results of pilot studies**	[redacted]
4.2	**Results of test**	
4.2.1	Challenge	Three of ten animals exhibited faint erythema (grade 1) after challenge. Faint erythema was also noted in two naïve control animals. Irritation decreased at both sites by 48 hours.
4.2.2	Re-challenge	Very faint erythema (grade 0.5) was noted at 7 of 10 animals 24 hours after re-challenge and in 4 of 5 naïve control animals. Irritation persisted at some animals through 48 hours.
4.2.3	Other findings	The positive control produced sensitisation in control animals and showed the sensitivity of the test system.
4.3	**Overall result**	IPBC is not considered to be a contact sensitiser.

5 APPLICANT'S SUMMARY AND CONCLUSION

5.1	**Materials and methods**	The study was performed according to OECD Guideline for Testing of Chemicals; Section 4: Health Effects, No. 406: "Skin Sensitisation" and according to US EPA 81-6 guideline. The Buehler method was used employing test animals, positive control and negative control animals[redacted]
5.2	**Results and discussion**	[redacted]
5.3	**Conclusion**	Not- sensitising
5.3.1	Reliability	[redacted]
5.3.2	Deficiencies	[redacted]

Section A6.1.5/01 Skin sensitisation

Annex Point IIA, VI.6.1.5 Buehler method

Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]
Materials and Methods	[redacted]
Results and discussion	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	

[redacted]

[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]

Section A6.1.5/02 Skin sensitisation

Annex Point IIA, VI.6.1.5 Guinea pig maximisation test (GPMT)

			Official use only
		1 REFERENCE	
1.1	**Reference**	[redacted] (1993): Troysan Polyphase P-100 The Guinea Pig Maximisation Test; [redacted] 24.08.1993 [redacted]	[redacted]
1.2	**Data protection**	[redacted]	
1.2.1	Data owner	[redacted]	
1.2.2	Companies with letter of access	[redacted]	
1.2.3	Criteria for data protection	[redacted]	
		2 GUIDELINES AND QUALITY ASSURANCE	
2.1	**Guideline study**	[redacted] OECD Guideline for Testing of Chemicals; Section 4: Health Effects, No. 406: "Skin Sensitisation" US EPA "Dermal Sensitisation" (81-6F)	[redacted]
2.2	**GLP**	[redacted]	
2.3	**Deviations**	Yes, the concentration used for topical induction in the main study, did not produce skin reactions in the animals of the main study.	
		3 MATERIALS AND METHODS	
3.1	**Test material**	[redacted]	
3.1.1	Lot/Batch number	[redacted]	
3.1.2	Specification	The purity of the test substance was slightly lower than the specification given in section 2. This does not influence the integrity of the study.	
3.1.3	Purity	[redacted]	
3.1.4	Description	[redacted]	
3.1.5	Stability	[redacted]	
3.1.5.1	Preparation of test substance for application	[redacted] c) [redacted]	
3.1.5.2	Pretest performed on irritant effects	[redacted]	

Section A6.1.5/02 Skin sensitisation

Annex Point IIA, VI.6.1.5 Guinea pig maximisation test (GPMT)

3.2	**Test Animals**	
3.2.1	Species	Guinea pigs
3.2.2	Strain	Dunkin/Hartley (SPF)
3.2.3	Source	[redacted]
3.2.4	Sex	female
3.2.5	Age/weight at study initiation	[redacted]
3.2.6	Number of animals per group	[redacted]
3.2.7	Control animals	[redacted]
3.3	**Administration/ Exposure**	
3.3.1	Induction schedule	day 0 (intradermal induction) day 6 (sodium lauryl sulphate exposure) day 7 (topical induction)
3.3.2	Way of Induction	Intradermal and topical
3.3.3	Concentrations used for induction	[redacted]
3.3.4	Concentration Freund's Complete Adjuvant (FCA)	[redacted]
3.3.5	Challenge schedule	[redacted]
3.3.6	Concentrations used for challenge	[redacted]
3.3.7	Rechallenge	[redacted]
3.3.8	Scoring schedule	[redacted] *
3.3.9	Removal of the test substance	[redacted]
3.3.10	Positive control substance	[redacted]

Section A6.1.5/02 Skin sensitisation

Annex Point IIA, VI.6.1.5 Guinea pig maximisation test (GPMT)

3.4 Examinations

3.4.1 Pilot study [redacted].

3.5 Further remarks None

4 RESULTS AND DISCUSSION

4.1 Results of pilot studies [redacted]

4.2 Results of test

4.2.1 24h after challenge [redacted]

4.2.2 48h after challenge [redacted]

4.2.3 72h after challenge [redacted]

4.2.4 Other findings [redacted]

4.3 Overall result IPBC exhibited no skin-sensitising potential. The sensitivity of the test system was shown.

Section A6.1.5/02 Skin sensitisation

Annex Point IIA, VI.6.1.5 Guinea pig maximisation test (GPMT)

5 APPLICANT'S SUMMARY AND CONCLUSION

5.1	**Materials and methods**	The study was performed according to OECD Guideline for Testing of Chemicals; Section 4: Health Effects, No. 406: "Skin Sensitisation"	*
5.2	**Results and discussion**	After the intradermal induction the test item animals showed strong skin reactions. The challenge with the 0.32% test item in petrolatum resulted in no skin reactions in the test item animals. It was concluded that IPBC had no skin-sensitising potential. The sensitity of the system was shown by the positive control	*
5.3	**Conclusion**	not-sensitising	*
5.3.1	Reliability	[redacted]	
5.3.2	Deficiencies	[redacted]	

Section A6.1.5/02 Skin sensitisation

Annex Point IIA, VI.6.1.5 Guinea pig maximisation test (GPMT)

Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]
Materials and Methods	[redacted]
Results and discussion	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	[redacted]

[redacted]

	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	
[redacted]	[redacted]		[redacted]
[redacted]	[redacted]		[redacted]
[redacted]	[redacted]		[redacted]

Section A6.1.5/03 Skin sensitisation

Annex Point IIA, VI.6.1.5 Guinea pig maximisation test (GPMT)

			Official use only
		1 REFERENCE	
1.1	**Reference**	[redacted] (2001): Preventol MP 100 Study for the skin sensitisation effect in guinea pigs (Guinea Pig Maximisation Test according to Magnusson and Kligman); [redacted] 25.01.2001	[redacted]
1.2	**Data protection**	[redacted]	
1.2.1	Data owner	[redacted]	
1.2.2	Companies with letter of access	[redacted]	
1.2.3	Criteria for data protection	[redacted]	
		2 GUIDELINES AND QUALITY ASSURANCE	
2.1	**Guideline study**	[redacted] OECD Guideline for Testing of Chemicals; Section 4: Health Effects, No. 406: "Skin Sensitisation" EC Guideline 96/54/EC (22nd Adaptation of Guideline 67/548/EEC): Classification, Packaging and Labelling of Hazardous Materials, "Skin Sensitisation", Method B.6 Health Effects Test Guidelines, OPPTS 870.2600 Skin Sensitisation: EPA 712-C-98-197, August 1998	[redacted]
2.2	**GLP**	[redacted]	
2.3	**Deviations**	No	
		3 MATERIALS AND METHODS	
3.1	**Test material**	[redacted]	
3.1.1	Lot/Batch number	[redacted]	
3.1.2	Specification	As given in section 2	
3.1.3	Purity	[redacted]	
3.1.4	Description	[redacted]	
3.1.5	Stability	[redacted]	
3.1.5.1	Preparation of test substance for application	[redacted] c) [redacted]	
3.1.5.2	Pretest performed	[redacted]	

Section A6.1.5/03 Skin sensitisation

Annex Point IIA, VI.6.1.5 Guinea pig maximisation test (GPMT)

	on irritant effects	
3.2	**Test Animals**	
3.2.1	Species	Guinea pigs
3.2.2	Strain	HSD Poc: DH (SPF-bred)
3.2.3	Source	[redacted]
3.2.4	Sex	female
3.2.5	Age/weight at study initiation	[redacted] *
3.2.6	Number of animals per group	[redacted]
3.2.7	Control animals	[redacted]
3.3	**Administration/ Exposure**	
3.3.1	Induction schedule	[redacted]
3.3.2	Way of Induction	Intradermal and topical
3.3.3	Concentrations used for induction	[redacted]
3.3.4	Concentration Freund's Complete Adjuvant (FCA)	[redacted]
3.3.5	Challenge schedule	[redacted]
3.3.6	Concentrations used for challenge	[redacted]
3.3.7	Rechallenge	[redacted]
3.3.8	Scoring schedule	[redacted]
3.3.9	Removal of the test substance	[redacted]
3.3.10	Positive control substance	[redacted]
3.4	**Examinations**	
3.4.1	Pilot study	[redacted]

Section A6.1.5/03 Skin sensitisation

Annex Point IIA, VI.6.1.5 Guinea pig maximisation test (GPMT)

3.5 Further remarks None

4 RESULTS AND DISCUSSION

4.1 Results of pilot studies

[redacted]

4.2 Results of test

4.2.1 48h after challenge [redacted]

4.2.2 72h after challenge [redacted]

4.2.3 Other findings [redacted]

4.3 Overall result IPBC exhibited a skin-sensitising potential. The sensitivity of the test system was assessed regularly.

Section A6.1.5/03 Skin sensitisation

Annex Point IIA, VI.6.1.5 Guinea pig maximisation test (GPMT)

5 APPLICANT'S SUMMARY AND CONCLUSION

5.2 Materials and methods

The study was performed according to OECD Guideline for Testing of Chemicals; Section 4: Health Effects, No. 406: "Skin Sensitisation"

5.3 Results and discussion

After the intradermal induction the test item animals showed strong effects up to encrustation at the injection sites. The challenge with the 5% test item formulation led to skin effects (grade 1) in 90% of the test item group and no skin effects were seen in the control group. It was concluded that IPBC had a skin-sensitising potential.

5.4 Conclusion

sensitising.

5.4.2 Reliability [redacted]

5.4.3 Deficiencies [redacted]

Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]
Materials and Methods	[redacted]
	[redacted]
Results and discussion	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	

Section A6.1.5/03 Skin sensitisation

Annex Point IIA, VI.6.1.5 Guinea pig maximisation test (GPMT)

[redacted]

Section A6.11/01 Acute Toxicity Intravenous, Rat

			Official use only
		1 REFERENCE	
1.1	**Reference**	[redacted]1988): Polyphase Cholinesterase Inhibition Study in Rats; [redacted] 22.04.1988	[redacted]
1.2	**Data protection**	[redacted]	
1.2.1	Data owner	[redacted]	
1.2.2	Companies with letter of access	[redacted]	
1.2.3	Criteria for data protection	[redacted]	
		2 GUIDELINES AND QUALITY ASSURANCE	
2.1	**Guideline study**	[redacted] US EPA Pesticide Assessment Guideline Subdivision F, 81-3	*
2.2	**GLP**	[redacted]	
2.3	**Deviations**	[redacted]	
		3 MATERIALS AND METHODS	
3.1	**Test material**	[redacted]	
3.1.1	Lot/Batch number	[redacted]	
3.1.2	Specification	As given in section 2	
3.1.3	Purity	[redacted]	
3.1.4	Description	[redacted]	
3.1.5	Stability	[redacted]	

Section A6.11/01 Acute Toxicity Intravenous, Rat

3.2	**Test Animals**	
3.2.1	Species	Rat
3.2.2	Strain	Sprague-Dawley
3.2.3	Source	[redacted]
3.2.4	Sex	males, females
3.2.5	Age/weight at study initiation	[redacted]
3.2.6	Number of animals per group	[redacted]
3.2.7	Control animals	[redacted]
3.3	**Administration/ Exposure**	intravenous
3.3.1	Postexposure period	[redacted]
3.3.2	Vehicle	[redacted]
3.3.3	Concentration in vehicle	[redacted]
3.3.4	Total volume applied	[redacted]
3.3.5	Controls	[redacted]
3.4	**Examinations**	[redacted]
3.5	**Method of determination of LD_{50}**	[redacted]
3.6	**Further remarks**	[redacted]

Section A6.11/01 Acute Toxicity Intravenous, Rat

4 RESULTS AND DISCUSSION

4.1	**Clinical signs**	[redacted]
4.2	**Pathology**	[redacted]
4.3	**RBC cholinesterase activity**	RBC cholinesterase activity was not reduced up to and including the highest dose (see Table A6.11/01-3)
4.4	**LD_{50}**	>16 mg/kg bw

5 APPLICANT'S SUMMARY AND CONCLUSION

5.1	**Materials and methods**	[redacted]
5.2	**Results and discussion**	[redacted]
5.3	**Conclusion**	LD_{50} > 16 mg/kg bw when IPBC is administered intravenously. RBC cholinesterase activity was not reduced up to and including 16 mg/kg bw (the highest dose investigated).
5.3.1	Reliability	[redacted]
5.3.2	Deficiencies	[redacted]

Section A6.11/01 Acute Toxicity Intravenous, Rat

Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]
Materials and Methods	[redacted]
	[redacted]
Results and discussion	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	[redacted]

[redacted]

[redacted]

[redacted]

Section A6.2/01 Toxicokinetic and metabolism in mammals

Annex Point IIA, VI.6.2 **Rat, gavage**

[redacted]

			Official use only
		1 REFERENCE	
1.1	**Reference**	[redacted] (1995): Metabolism of ^{14}C-IPBC in Rats [redacted], 01.03.1995	[redacted]
1.2	**Data protection**	[redacted]	
1.2.1	Data owner	[redacted]	
1.2.2	Companies with letter of access	[redacted]	
1.2.3	Criteria for data protection	[redacted]	
		2 GUIDELINES AND QUALITY ASSURANCE	
2.1	**Guideline study**	[redacted] EPA guideline Series 85-1, which is comparable to OECD guideline 417	
2.2	**GLP**	[redacted]	
2.3	**Deviations**	[redacted]	
		3 MATERIALS AND METHODS	
3.1	**Test material**	a) radiolabelled IPBC: 3-Iodo-2-[2-^{14}C]Propynyl-N-[1-^{14}C]-Butyl Carbamate b) unlabelled IPBC	
3.1.1	Lot/Batch number	[redacted]	
3.1.2	Specification	a) Not applicable, radiolabelled IPBC b) As given in section 2	
3.1.3	Purity	[redacted]	
3.1.4	Description	[redacted]	
3.1.5	Stability	[redacted]	

Section A6.2/01 Toxicokinetic and metabolism in mammals

Annex Point IIA, VI.6.2 **Rat, gavage**

3.2	**Test Animals**	
3.2.1	Species	Rat
3.2.2	Strain	Crl:CD®BR
3.2.3	Source	[redacted]
3.2.4	Sex	male, female
3.2.5	Age/weight at study initiation	[redacted]
3.2.6	Number of animals per group	[redacted]
3.3	**Administration/ Exposure**	Oral
3.3.1	Dosing regime	[redacted]
3.3.2	Type	Gavage
3.3.3	Vehicle	[redacted]
3.3.4	Concentration in vehicle	[redacted]
3.3.5	Total volume applied	[redacted]
3.3.6	Controls	[redacted]
3.4	**Examinations**	
3.4.1	Excretion routes	[redacted]
3.4.2	Body fluids sampled	[redacted]
3.4.3	Tissues sampled	[redacted]
3.5	**Statistics**	[redacted]
3.6	**Further remarks**	[redacted]

Section A6.2/01 Toxicokinetic and metabolism in mammals
Annex Point IIA, VI.6.2 Rat, gavage

4 RESULTS AND DISCUSSION

4.1 Excretion balance

[redacted]

4.2 Tissue distribution

[redacted]

*

Section A6.2/01 **Toxicokinetic and metabolism in mammals**
Annex Point IIA, VI.6.2 **Rat, gavage**

4.3 Metabolites



4.4 Absorption

Section A6.2/01 Toxicokinetic and metabolism in mammals

Annex Point IIA, VI.6.2 **Rat, gavage**

5 APPLICANT'S SUMMARY AND CONCLUSION

5.1 Materials and methods

The study was conducted according to EPA guideline 85-1 which is comparable to OECD guideline 417.

[redacted]

5.2 Results and discussion

The majority of the administered radioactivity was excreted via urine (57.3% to 70.7%). A smaller amount was recovered in exhaled air (18.3 to 24.0%), 4.4% to 7.44% of administered radioactivity were recovered in faeces. The majority of radioactivity was excreted within 72 hours (77 to 99% of administered radioactivity).

IPBC was widely distributed. The concentration of radioactivity declined in the tissues with time. There was no trend for bioaccumulation observable. Less than 3.1% of the dose were recovered in carcass and tissues after 14 days. *

[redacted]

On the basis of the excretion balance and metabolite pattern, it is concluded that IPBC was completely absorbed via the oral route.

There were no differences between sexes or applied doses detectable.

5.3 Conclusion

see Results and Discussion

5.3.1 Reliability [redacted]

5.3.2 Deficiencies [redacted]

Section A6.2/01 Toxicokinetic and metabolism in mammals

Annex Point IIA, VI.6.2 **Rat, gavage**

	Evaluation by Competent Authorities
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]
Materials and Methods	[redacted]
Results and discussion	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	

[redacted]

[redacted]						
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]						
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	
[redacted]		[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	
[redacted]		[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]	[redacted]	[redacted]	
[redacted]		[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	
[redacted]		[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	
[redacted]		[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]		[redacted]	[redacted]	[redacted]	[redacted]	[redacted]

[redacted]



[redacted]

[redacted]

[redacted]	[redacted]							
	[redacted]				[redacted]			
	[redacted]		[redacted]		[redacted]		[redacted]	
	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]			[redacted]	[redacted]		
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]			[redacted]	[redacted]		
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]			[redacted]	[redacted]		
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]			[redacted]	[redacted]		
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]			[redacted]	[redacted]		
[redacted]	[redacted]	[redacted]			[redacted]	[redacted]		
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]			[redacted]	[redacted]		
[redacted]	[redacted]	[redacted]			[redacted]	[redacted]		
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]

[redacted]

[redacted]

[redacted]

[redacted]

	[redacted]															
	[redacted]						[redacted]						[redacted]			
[redacted]	[redacted]		[redacted]		[redacted]		[redacted]		[redacted]		[redacted]		[redacted]		[redacted]	
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]																
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]										
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]																
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]																
[redacted]																
[redacted]																
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]

[redacted]

20/

[redacted]

	[redacted]															
	[redacted]						[redacted]						[redacted]			
[redacted]																
[redacted]																
[redacted]																
[redacted]																
[redacted]																
[redacted]																
[redacted]																
[redacted]																
[redacted]																
[redacted]																
[redacted]																
[redacted]																
[redacted]																
[redacted]																
[redacted]																
[redacted]																
[redacted]																
[redacted]																
[redacted]																

[redacted]



Figure A6.2/01-1: Proposed metabolic pathway of ^{14}C-IPBC after oral administration (percentages are based on total dose administered)

Section A6.2/02 Percutaneous absorption *in vitro*, human skin

Annex Point IIA, VI.6.2

1 REFERENCE

Official use only

1.1 Reference

[redacted] (1995): The In Vitro Percutaneous Absorption Through Human Abdominal Epidermis of [^{14}C]-IPBC (3-Iodo-2-Propynyl-n-Butyl Carbamate); [redacted] 27.09.1995;

1.2 Data protection

[redacted]

1.2.1 Data owner

[redacted]

1.2.2 Companies with letter of access

[redacted]

1.2.3 Criteria for data protection

[redacted]

2 GUIDELINES AND QUALITY ASSURANCE

2.1 Guideline study

[redacted]

UK HSE Control of Pesticides Regulations 1986 (Data requirements requested by Scientific Sub-Committee on Pesticides (SCP)). The method used is comparable to the OECD Draft guideline 428 "Skin Absorption: *in vitro* method"

2.2 GLP

[redacted]

2.3 Deviations

Yes, the sampling time of the receptor fluid was 8 hours (24 hours are recommended). There is no information about the solubility of the test substance in the receptor fluid.

3 MATERIALS AND METHODS

3.1 Test material

The following materials were supplied to the contract laboratory:

a) radiolabelled IPBC
b) unlabelled IPBC

[redacted]

3.1.1 Lot/Batch number

[redacted]

Section A6.2/02 Percutaneous absorption

Annex Point IIA, VI.6.2 ***in vitro*, human skin**

[redacted]

3.1.2 Specification: not applicable, different formulations

3.1.3 Purity: [redacted]

3.1.4 Description: [redacted]

3.1.5 Radiolabelling: ^{14}C, 3-Iodo-2-[2-^{14}C]-Propynyl-N-[1-^{14}C]-Butyl carbamate

3.1.6 Concentration in the formulations: [redacted]

3.1.7 Stability: [redacted]

Section A6.2/02 Percutaneous absorption

Annex Point IIA, VI.6.2 ***in vitro*, human skin**

[redacted]

3.2	**Human Skin**	
3.2.1	Preparation of human skin	[redacted]
3.2.2	Type of skin	abdominal
3.2.3	Source	autopsy skin
3.2.4	Storage condition	[redacted]
3.2.5	Number and age of donors	[redacted]3 males (49 to 82 years old), 4 females (53 to 73 years old)
3.2.6	Number of replicates	[redacted]
3.3	**Diffusion Apparatus**	
3.3.1	Equipment and settings	[redacted]
3.3.2	Equilibration period before exposure	[redacted]
3.3.3	Receptor fluid	[redacted]
3.3.4	Skin integrity	[redacted]
3.4	**Administration**	
3.4.1	Application volume	[redacted]
3.4.2	Applied radioactivity per replicate	[redacted]
3.4.3	Exposed area	[redacted]
3.4.4	Mode of application	[redacted]
3.4.5	Temperature	[redacted]

Section A6.2/02 — Percutaneous absorption

Annex Point IIA, VI.6.2 — ***in vitro*, human skin**

3.4.6	Duration of exposure	[redacted]
3.4.7	Duration of post-exposure	[redacted]
3.4.8	Skin Washing	[redacted]
3.4.9	Tape Stripping	[redacted]
3.4.10	Positive controls	[redacted]
	4 RESULTS AND DISCUSSION	
4.1	**Recovery**	
4.1.1	Total recovery	[redacted]
4.1.2	Amount of radioactivity in skin	[redacted]
4.1.3	Total amount of radioactivity in receptor fluid	[redacted]
4.1.4	Amount of radioactivity in receptor rinse	[redacted]
4.1.5	Amount of radioactivity in washing	[redacted]
4.1.6	Amount of radioactivity in tape strips	[redacted]
4.2	**Method of analysis**	[redacted]

Section A6.2/02 Percutaneous absorption

Annex Point IIA, VI.6.2 ***in vitro*, human skin**

4.3	Absorption	[redacted]	*

Section A6.2/02 Percutaneous absorption

Annex Point IIA, VI.6.2 *in vitro*, human skin

5 APPLICANT'S SUMMARY AND CONCLUSION

5.1 Materials and methods

In an *in vitro* dermal penetration study, three IPBC containing, solvent-based formulations were tested: [redacted]

5.2 Results and discussion

The absorbed percentages [redacted] were: 0.8, 3.7, and 26.3% of the applied dose, respectively. *

5.3 Conclusion

[redacted]

5.3.1 Reliability

[redacted]

5.3.2 Deficiencies

[redacted]

Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]
Materials and Methods	[redacted]
Results and discussion	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	

Section A6.2/02 Percutaneous absorption

Annex Point IIA, VI.6.2 *in vitro*, human skin



Section A6.3.1/01 Repeated/Subacute toxicity (28 days + 14 days recovery)

Annex Point IIA, VI.6.3 **Gavage Rat**

[redacted]

1 REFERENCE

Official use only

1.1	**Reference**	[redacted] (2001): Institute of Toxicology, Department of Short-Term Rodent Studies and Neurotoxicology; [redacted] 24.04.2001 [redacted]
1.2	**Data protection**	[redacted]
1.2.1	Data owner	[redacted]
1.2.2	Companies with letter of access	[redacted]
1.2.3	Criteria for data protection	[redacted]

2 GUIDELINES AND QUALITY ASSURANCE

2.1	**Guideline study**	Yes, OECD Guideline No. 407 (adopted 1995) Guideline 67/548/EEC B.7 (adopted 1996) „Toxicity after administration for 28 days (oral)“ Notification No. 700 of Kanpogyo, No. 1039 of Yakuhatsu, and No. 1014 of 61 Kikyoku, December 1986 28-day Repeated Dose Toxicity Study in Mammalian Species“
2.2	**GLP**	[redacted]
2.3	**Deviations**	No

3 MATERIALS AND METHODS

3.1	**Test material**	[redacted]
3.1.1	Lot/Batch number	[redacted]
3.1.2	Specification	As given in section 2
3.1.3	Purity	[redacted]
3.1.4	Description	[redacted]
3.1.5	Stability	[redacted]
3.2	**Test Animals**	
3.2.1	Species	Rat
3.2.2	Strain	Wistar Hsd Cpd:WU (SPF bred)

Section A6.3.1/01 Repeated/Subacute toxicity (28 days + 14 days recovery)

Annex Point IIA, VI.6.3 **Gavage Rat**

3.2.3	Source	[redacted]
3.2.4	Sex	male, female
3.2.5	Age/weight at study initiation	[redacted]
3.2.6	Number of animals per group	[redacted]
3.2.7	Control animals	[redacted]
3.3	**Administration/ Exposure**	Oral
3.3.1	Duration of treatment	[redacted]
3.3.2	Frequency of exposure	[redacted]
3.3.3	Post-exposure period	[redacted]
3.3.4	Type	[redacted]
3.3.5	Concentration	[redacted]
3.3.6	Vehicle	[redacted]
3.3.7	Concentration in vehicle	[redacted]
3.3.8	Total volume applied	[redacted]
3.3.9	Controls	[redacted]
3.4	**Examinations**	
3.4.1	Observations	
3.4.1.1	Clinical signs	[redacted]
3.4.1.2	Mortality	[redacted]
3.4.2	Body weight	[redacted]
3.4.3	Food consumption	[redacted]
3.4.4	Water consumption	[redacted]
3.4.5	Ophthalmoscopic examination	[redacted]
3.4.6	Haematology	[redacted]
3.4.7	Clinical Chemistry	[redacted]

Section A6.3.1/01 Repeated/Subacute toxicity (28 days + 14 days recovery)

Annex Point IIA, VI.6.3 **Gavage Rat**

[redacted]

3.4.8 Urinalysis

3.5 Sacrifice and pathology

3.5.1 Organ Weights

3.5.2 Gross and histopathology

3.5.3 Other examinations

3.5.4 Statistics

3.6 Further remarks

4 **RESULTS AND DISCUSSION**

4.1 Observations

4.1.1 Clinical signs

4.1.2 Mortality

4.2 Body weight gain

Section A6.3.1/01 Repeated/Subacute toxicity (28 days + 14 days recovery)

Annex Point IIA, VI.6.3 **Gavage Rat**

4.3 Food consumption and compound intake

[redacted]

4.4 Ophthalmoscopic examination

[redacted]

4.5 Blood analysis

4.5.1 Haematology

[redacted]

4.5.2 Clinical chemistry

[redacted] *

Section A6.3.1/01 **Repeated/Subacute toxicity (28 days + 14 days recovery)**

Annex Point IIA, VI.6.3 **Gavage Rat**

4.5.3	Urinalysis	
4.5.4	FOB	
4.5.5	Motor activity	
4.6	**Sacrifice and pathology**	
4.6.1	Gross pathology	
4.6.2	Organ weights and histopathology	* *

Section A6.3.1/01 Repeated/Subacute toxicity (28 days + 14 days recovery)

Annex Point IIA, VI.6.3 Gavage Rat

[redacted]

5 APPLICANT'S SUMMARY AND CONCLUSION

5.1 Materials and methods

[redacted]

The study was conducted according to OECD Guideline No. 407 (adopted 1995), Guideline 67/548/EEC B.7 (adopted 1996) „Toxicity after administration for 28 days (oral)", and Notification No. 700 of Kanpogyo, No. 1039 of Yakuhatsu, and No. 1014 of 61 Kikyoku, December 1986 „28-day Repeated Dose Toxicity Study in Mammalian Species".

5.2 Results and discussion

[redacted]

*

Section A6.3.1/01 Repeated/Subacute toxicity (28 days + 14 days recovery)

Annex Point IIA, VI.6.3 **Gavage Rat**

5.3	**Conclusion**		
5.3.1	NOEL	10 mg/kg bw/day for both sexes	*
5.3.2	NOAEL	30 mg/kg bw/day for both sexes, based on chronic peritonitis at 100 mg/kg bw/day.	*
5.3.3	Other	LOEL 100 mg/kg bw/day	*
5.3.4	Reliability	[redacted]	
5.3.5	Deficiencies	No	

Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]
Materials and Methods	[redacted]
Results and discussion	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	





Section A6.3.1/02/03 Repeated/subacute toxicity (4 weeks)

Annex Point IIA, VI.6.3 Feeding Rat

			Official use only
		1 REFERENCE	
1.1	**Reference**	A6.3.1/02: [redacted] (1986): Iodopropynylbutyl Carbamate (IPBC) 4 Week Dietary Dose Range Finding Study in Rats; [redacted] 30.09.1986 [redacted] A6.3.1/03: [redacted] (1986): Establishment of Methodology and the Routine Analysis of Iodopropynylbutyl carbamate in Diets prepared for a 4 Week Dose Range Finding Study in the Rat [redacted] 01.09.1986 [redacted]	[redacted]
1.2	**Data protection**	[redacted]	
1.2.1	Data owner	[redacted]	
1.2.2	Companies with letter of access	[redacted]	
1.2.3	Criteria for data protection	[redacted]	
		2 GUIDELINES AND QUALITY ASSURANCE	
2.1	**Guideline study**	A6.3.1/02: No, rangefinding study A6.3.1/03: not applicable, analytical methods	
2.2	**GLP**	[redacted]	
2.3	**Deviations**	A6.3.1/02 and A6.3.1/03: not applicable	
		3 MATERIALS AND METHODS	
3.1	**Test material**	[redacted]	
3.1.1	Lot/Batch number	[redacted]	
3.1.2	Specification	The purity of the test substance was slightly lower than the specification given in section 2. This dose not influence the integrity of the study.	
3.1.3	Purity	[redacted]	
3.1.4	Description	[redacted]	

Section A6.3.1/02/03 Repeated/subacute toxicity (4 weeks)

Annex Point IIA, VI.6.3 **Feeding Rat**

3.1.5	Stability	[redacted]
3.2	**Test Animals**	
3.2.1	Species	Rat
3.2.2	Strain	Sprague-Dawley
3.2.3	Source	[redacted]
3.2.4	Sex	male, female
3.2.5	Age/weight at study initiation	[redacted]
3.2.6	Number of animals per group	[redacted]
3.2.7	Control animals	[redacted]
3.3	**Administration/ Exposure**	Oral
3.3.1	Duration of treatment	[redacted]
3.3.2	Frequency of exposure	[redacted]
3.3.3	Post-exposure period	[redacted]
3.3.4	Type	[redacted]
3.3.5	Concentration	[redacted] *
3.3.6	Vehicle	[redacted]
3.3.7	Concentration in vehicle	[redacted]
3.3.8	Total volume applied	[redacted]
3.3.9	Controls	[redacted]

Section A6.3.1/02/03 Repeated/subacute toxicity (4 weeks)

Annex Point IIA, VI.6.3 **Feeding Rat**

3.4	**Examinations**	
3.4.1	Observations	
3.4.1.1	Clinical signs	[redacted]
3.4.1.2	Mortality	[redacted]
3.4.2	Body weight	[redacted]
3.4.3	Food consumption	[redacted]
3.4.4	Water consumption	[redacted]
3.4.5	Ophthalmoscopic examination	[redacted]
3.4.6	Haematology	[redacted]
3.4.7	Clinical Chemistry	[redacted]
3.4.8	Urinalysis	[redacted]
3.5	**Sacrifice and pathology**	
3.5.1	Organ Weights	[redacted]
3.5.2	Gross and histopathology	[redacted]
3.5.3	Other examinations	[redacted]
3.5.4	Statistics	[redacted]
3.6	**Further remarks**	[redacted]
	4 RESULTS AND DISCUSSION	
4.1	**Observations**	
4.1.1	Clinical signs	[redacted]
4.1.2	Mortality	[redacted]
4.2	**Body weight gain**	[redacted]
4.3	**Food consumption**	[redacted]

Section A6.3.1/02/03 Repeated/subacute toxicity (4 weeks)

Annex Point IIA, VI.6.3 **Feeding Rat**

4.4	**Water consumption**	[redacted]
4.5	**Ophthalmoscopic examination**	[redacted]
4.6	**Blood analysis**	
4.6.1	Haematology	[redacted]
4.6.2	Clinical chemistry	[redacted]
4.6.3	Urinalysis	[redacted]
4.7	**Sacrifice and pathology**	
4.7.1	Organ weights	[redacted] *
4.7.2	Gross and histopathology	[redacted]
4.8	**Other**	[redacted]

Section A6.3.1/02/03 Repeated/subacute toxicity (4 weeks)

Annex Point IIA, VI.6.3 **Feeding Rat**

5 APPLICANT'S SUMMARY AND CONCLUSION

5.1 Materials and methods

[redacted]

5.2 Results and discussion

[redacted] *

5.3 Conclusion

5.3.1	LO(A)EL	Not applicable dose-rangefinder
5.3.2	NO(A)EL	Not applicable dose-rangefinder
5.3.3	Other	
5.3.4	Reliability	[redacted]
5.3.5	Deficiencies	Yes, Haematology was not performed, clinical chemistry analysis was restricted to determination of cholinesterase activity. The only organ examined by histopathology was liver. However, as this was a range-finding study, this is of minor importance.

Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	Evaluation by Rapporteur Member State
Date	[redacted]
Materials and Methods	[redacted]

Section A6.3.1/02/03 Repeated/subacute toxicity (4 weeks)

Annex Point IIA, VI.6.3 **Feeding Rat**

Results and discussion	[redacted]
Conclusion	
Reliability	
Acceptability	
Remarks	

[redacted]

[redacted]

Section A6.3.1/04 Repeated/subacute toxicity (2 weeks)

Annex Point IIA, VI.6.3 Feeding Rabbit

			Official use only
		1 REFERENCE	
1.1	**Reference**	[redacted] (1996): A 2-Week Range-Finding Study of Troysan Polyphase P100 in the Rabbit Via Dietary Administration [redacted] 08.05.1996; [redacted]	[redacted]
1.2	**Data protection**	[redacted]	
1.2.1	Data owner	[redacted]	
1.2.2	Companies with letter of access	[redacted]	
1.2.3	Criteria for data protection	[redacted]	
		2 GUIDELINES AND QUALITY ASSURANCE	
2.1	**Guideline study**	No, dose-rangefindmg study	
2.2	**GLP**	[redacted]	
2.3	**Deviations**	[redacted]	
		3 MATERIALS AND METHODS	
3.1	**Test material**	[redacted]	
3.1.1	Lot/Batch number	[redacted]	
3.1.2	Specification	As given in section 2	
3.1.3	Purity	[redacted]	*
3.1.4	Description	[redacted]	
3.1.5	Stability	[redacted]	

Section A6.3.1/04 Repeated/subacute toxicity (2 weeks)

Annex Point IIA, VI.6.3 Feeding Rabbit

3.2	**Test Animals**	
3.2.1	Species	Rabbit
3.2.2	Strain	New Zealand White
3.2.3	Source	[redacted]
3.2.4	Sex	male, female
3.2.5	Age/weight at study initiation	[redacted]
3.2.6	Number of animals per group	[redacted]
3.2.7	Control animals	[redacted]
3.3	**Administration/ Exposure**	Oral
3.3.1	Duration of treatment	[redacted]
3.3.2	Frequency of exposure	[redacted]
3.3.3	Post-exposure period	[redacted]
3.3.4	Type	[redacted]
3.3.5	Concentration	[redacted] *
3.3.6	Vehicle	[redacted]
3.3.7	Concentration in vehicle	[redacted]
3.3.8	Total volume applied	[redacted]
3.3.9	Controls	[redacted]
3.4	**Examinations**	
3.4.1	Observations	
3.4.1.1	Clinical signs	[redacted]
3.4.1.2	Mortality	[redacted]
3.4.2	Body weight	[redacted]
3.4.3	Food consumption	[redacted]
3.4.4	Water consumption	[redacted]

Section A6.3.1/04 **Repeated/subacute toxicity (2 weeks)**

Annex Point IIA, VI.6.3 **Feeding Rabbit**

3.4.5 Ophthalmoscopic examination

3.4.6 Haematology

3.4.7 Clinical Chemistry

3.4.8 Urinalysis

3.5 Sacrifice and pathology

3.5.1 Organ Weights

3.5.2 Gross pathology

3.5.3 Other examinations

3.5.4 Statistics

3.6 Further remarks

4 **RESULTS AND DISCUSSION**

4.1 Observations

4.1.1 Clinical signs

4.1.2 Mortality

4.2 Body weight gain

4.3 Food consumption and compound intake

4.4 Ophthalmoscopic examination

Section A6.3.1/04 Repeated/subacute toxicity (2 weeks)

Annex Point IIA, VI.6.3 Feeding Rabbit

4.5	**Blood analysis**	
4.5.1	Haematology	[redacted]
4.5.2	Clinical chemistry	[redacted]
4.5.3	Urinalysis	[redacted]
4.6	**Sacrifice and pathology**	
4.6.1	Organ weights	[redacted]
4.6.2	Gross and histopathology	[redacted]
4.7	**Other**	[redacted]

5 APPLICANT'S SUMMARY AND CONCLUSION

5.1	**Materials and methods**	[redacted] *
5.2	**Results and discussion**	[redacted]
5.3	**Conclusion**	
5.3.1	LO(A)EL	not applicable, dose-rangefinder
5.3.2	NOAEL	not applicable, dose-rangefinder
5.3.3	Other	[redacted]
5.3.4	Reliability	[redacted]
5.3.5	Deficiencies	No

Section A6.3.1/04 Repeated/subacute toxicity (2 weeks)

Annex Point IIA, VI.6.3 **Feeding Rabbit**

Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	Evaluation by Rapporteur Member State
Date	[redacted]
Materials and Methods	[redacted]
Results and discussion	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	

[redacted]

Section A6.3.1/05 Repeated/subacute toxicity (8 weeks)

Annex Point IIA, VI.6.3 **Feeding Mice**

			Official use only
		1 REFERENCE	
1.1	**Reference**	[redacted] (1987): Iodopropynylbutyl carbamate (IPBC) 8 Week Dietary Dose Range Finding Study in Mice: [redacted] 26.10.1987	[redacted]
1.2	**Data protection**	[redacted]	
1.2.1	Data owner	[redacted]	
1.2.2	Companies with letter of access	[redacted]	
1.2.3	Criteria for data protection	[redacted]	
		2 GUIDELINES AND QUALITY ASSURANCE	
2.1	**Guideline study**	No, dose-rangefinding study	
2.2	**GLP**	[redacted]	
2.3	**Deviations**	Not applicable	
		3 MATERIALS AND METHODS	
3.1	**Test material**	[redacted]	
3.1.1	Lot/Batch number	[redacted]	
3.1.2	Specification	The purity of the test substance was slightly lower than the specification given in section 2. This does not influence the integrity of the study.	
3.1.3	Purity	[redacted]	
3.1.4	Description	[redacted]	
3.1.5	Stability	[redacted]	
3.2	**Test Animals**		
3.2.1	Species	Mouse	
3.2.2	Strain	CD-1	
3.2.3	Source	[redacted]	
3.2.4	Sex	male, female	
3.2.5	Age/weight at study initiation	[redacted]	
3.2.6	Number of animals per group	[redacted]	
3.2.7	Control animals	[redacted]	

Section A6.3.1/05 Repeated/subacute toxicity (8 weeks)

Annex Point IIA, VI.6.3 **Feeding Mice**

3.3	**Administration/ Exposure**	Oral
3.3.1	Duration of treatment	
3.3.2	Frequency of exposure	
3.3.3	Post-exposure period	
3.3.4	Type	
3.3.5	Concentration	
3.3.6	Vehicle	
3.3.7	Concentration in vehicle	
3.3.8	Total volume applied	
3.3.9	Controls	
3.4	**Examinations**	
3.4.1	Observations	
3.4.1.1	Clinical signs	
3.4.1.2	Mortality	
3.4.2	Body weight	
3.4.3	Food consumption	
3.4.4	Water consumption	
3.4.5	Ophthalmoscopic examination	
3.4.6	Haematology	
3.4.7	Clinical Chemistry	
3.4.8	Urinalysis	
3.5	**Sacrifice and pathology**	
3.5.1	Organ Weights	
3.5.2	Gross pathology	
3.5.3	Histopathology	
3.5.4	Other examinations	

Section A6.3.1/05 Repeated/subacute toxicity (8 weeks)

Annex Point IIA, VI.6.3 **Feeding Mice**

3.5.5 Statistics

3.6 Further remarks

4 **RESULTS AND DISCUSSION**

4.1 Observations

4.1.1 Clinical signs

4.1.2 Mortality

4.2 Body weight gain

4.3 Food consumption

4.4 Water consumption

4.5 Ophthalmoscopic examination

4.6 Blood analysis

4.6.1 Haematology

4.6.2 Clinical chemistry

4.6.3 Urinalysis

Section A6.3.1/05 Repeated/subacute toxicity (8 weeks)

Annex Point IIA, VI.6.3 **Feeding Mice**

4.7 Sacrifice and pathology

4.7.1 Organ weights

[redacted]

4.7.2 Gross and histopathology

[redacted]

4.8 Other

[redacted]

5 APPLICANT'S SUMMARY AND CONCLUSION

5.1 Materials and methods

[redacted]

Section A6.3.1/05 Repeated/subacute toxicity (8 weeks)

Annex Point IIA, VI.6.3 **Feeding Mice**

5.2	**Results and discussion**	[redacted]
5.3	**Conclusion**	
5.3.1	LO(A)EL	Not applicable, dose-rangefinding
5.3.2	NOAEL	Not applicable, dose-rangefinding
5.3.3	Other	[redacted]
5.3.4	Reliability	[redacted]
5.3.5	Deficiencies	No

Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	Evaluation by Rapporteur Member State
Date	[redacted]
Materials and Methods	[redacted]
Results and discussion	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	





Section A6.3.2 Annex Point IIA, VI.6.3	Repeated/subacute toxicity dermal	
	JUSTIFICATION FOR NON-SUBMISSION OF DATA	Official use only
Other existing data [X]	**Technically not feasible [ ]** **Scientifically unjustified [ ]**	
Limited exposure [ ]	**Other justification [ ]**	
Detailed justification:	A subacute dermal toxicity study is not required if a GLP and guideline compliant subchronic dermal toxicity study is available. The 90-day dermal toxicity study in rats is summarised in Siglin, 1991, Doc. No. 534-001, Doc. IIIA, Section A6.4.2/01. The submission of a subacute dermal toxicity study is, thus, not required.	
	Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted	
	EVALUATION BY RAPPORTEUR MEMBER STATE	
Date	[redacted]	
Evaluation of applicant's justification	[redacted]	
Conclusion	[redacted]	
Remarks		

Section A6.3.3/01 Repeated/subacute toxicity (2 weeks)

Annex Point IIA, VI.6.3 Inhalation Rat

			Official use only
		1 REFERENCE	
1.1	**Reference**	[redacted] (1994): Omacide® IPBC 2-Week Repeat Dose Inhalation Toxicity Study in Rats; [redacted]	[redacted]
1.2	**Data protection**	[redacted]	
1.2.1	Data owner	[redacted]	
1.2.2	Companies with letter of access	[redacted]	
1.2.3	Criteria for data protection	[redacted]	
		2 GUIDELINES AND QUALITY ASSURANCE	
2.1	**Guideline study**	No, dose-rangefinding study for subsequent 90-day inhalation toxicity study.	
2.2	**GLP**	[redacted]	
2.3	**Deviations**	Not appliable	
		3 MATERIALS AND METHODS	
3.1	**Test material**	[redacted]	
3.1.1	Lot/Batch number	[redacted]	
3.1.2	Specification	The purity of the test substance was slightly lower than the specification given in section 2. This does not influence the integrity of the study.	
3.1.3	Purity	[redacted]	
3.1.4	Description	[redacted]	
3.1.5	Stability	[redacted]	
3.2	**Test Animals**		
3.2.1	Species	Rat	
3.2.2	Strain	Sprague Dawley	
3.2.3	Source	[redacted]	
3.2.4	Sex	male, female	
3.2.5	Age/weight at study initiation	[redacted]	
3.2.6	Number of animals per group	[redacted]	
3.2.7	Control animals	[redacted]	

Section A6.3.3/01 Repeated/subacute toxicity (2 weeks)

Annex Point IIA, VI.6.3 Inhalation Rat

3.3	**Administration/ Exposure**	Inhalation
3.3.1	Duration of treatment	
3.3.2	Frequency of exposure	
3.3.3	Post-exposure period	
3.3.4	Concentrations	
3.3.5	Particle size	
3.3.6	Type or preparation of particles	
3.3.7	Type of exposure	
3.3.8	Vehicle	
3.3.9	Concentration in vehicle	
3.3.10	Duration of exposure	
3.3.11	Controls	
3.4	**Examinations**	
3.4.1	Observations	
3.4.1.1	Clinical signs	
3.4.1.2	Mortality	
3.4.2	Body weight	
3.4.3	Food consumption	
3.4.4	Water consumption	
3.4.5	Ophthalmoscopic examination	
3.4.6	Haematology	
3.4.7	Clinical Chemistry	

Section A6.3.3/01 Repeated/subacute toxicity (2 weeks)

Annex Point IIA, VI.6.3 Inhalation Rat

3.4.8 Urinalysis [redacted]

3.5 Sacrifice and pathology

3.5.1 Organ Weights [redacted]

3.5.2 Gross and histopathology [redacted]

3.5.3 Other examinations

3.5.4 Statistics [redacted]

3.6 Further remarks None

***4* RESULTS AND DISCUSSION**

4.1 Observations

4.1.1 Clinical signs [redacted]

4.1.2 Mortality [redacted]

4.2 Body weight gain [redacted]

Section A6.3.3/01 Repeated/subacute toxicity (2 weeks)

Annex Point IIA, VI.6.3 Inhalation Rat

4.3	**Food consumption**	
4.4	**Water consumption**	
4.5	**Ophthalmoscopic examination**	
4.6	**Blood analysis**	
4.6.1	Haematology	
4.6.2	Clinical chemistry	
4.6.3	Urinalysis	
4.7	**Sacrifice and pathology**	
4.7.1	Organ weights	
4.7.2	Gross and histopathology	

Section A6.3.3/01 Repeated/subacute toxicity (2 weeks)

Annex Point IIA, VI.6.3 **Inhalation Rat**

[redacted]

4.8 Other

5 APPLICANT'S SUMMARY AND CONCLUSION

5.1 Materials and methods

[redacted] *

5.2 Results and discussion

[redacted]

Section A6.3.3/01 Repeated/subacute toxicity (2 weeks)

Annex Point IIA, VI.6.3 **Inhalation Rat**

[redacted] *

5.3	**Conclusion**	
5.3.1	LOAEL	not relevant, rangefinding study
5.3.2	NOEL	not relevant, rangefinding study
5.3.3	Other	
5.3.4	Reliability	[redacted]
5.3.5	Deficiencies	No

	Evaluation by Competent Authorities
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]
Materials and Methods	[redacted]
Results and discussion	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	



Section A6.3.3/02 Repeated dose toxicity (5 days)

Annex Point IIA, VI.6.3 **Inhalation Rat**

			Official use only
		1 REFERENCE	
1.1	**Reference**	[redacted] (1994): Omacide® IPBC 5-Day Repeat Dose Inhalation Toxicity Study in Rats; Hu[redacted]	[redacted]
1.2	**Data protection**	[redacted]	
1.2.1	Data owner	[redacted]	
1.2.2	Companies with letter of access	[redacted]	
1.2.3	Criteria for data protection	[redacted]	
		2 GUIDELINES AND QUALITY ASSURANCE	
2.1	**Guideline study**	No, dose-rangefinding study for subsequent 90-day inhalation toxicity study.	
2.2	**GLP**	[redacted]	
2.3	**Deviations**	[redacted]	
		3 MATERIALS AND METHODS	
3.1	**Test material**	[redacted]	
3.1.1	Lot/Batch number	[redacted]	
3.1.2	Specification	The purity of the test substance was slightly lower than the specification given in section 2. This does not influence the integrity of the study.	
3.1.3	Purity	[redacted]	
3.1.4	Description	[redacted]	
3.1.5	Stability	[redacted]	
3.2	**Test Animals**		
3.2.1	Species	Rat	
3.2.2	Strain	Sprague Dawley	
3.2.3	Source	[redacted]	
3.2.4	Sex	male, female	
3.2.5	Age/weight at study initiation	[redacted]	
3.2.6	Number of animals per group	[redacted]	
3.2.7	Control animals	[redacted]	
3.3	**Administration/ Exposure**	Inhalation	

Section A6.3.3/02 Repeated dose toxicity (5 days)

Annex Point IIA, VI.6.3 **Inhalation Rat**

3.3.1	Duration of treatment	[redacted]
3.3.2	Frequency of exposure	[redacted]
3.3.3	Post-exposure period	[redacted]
3.3.4	Concentrations	[redacted]
3.3.5	Particle size	[redacted] *
3.3.6	Type or preparation of particles	[redacted]
3.3.7	Type of exposure	Whole body
3.3.8	Vehicle	[redacted]
3.3.9	Concentration in vehicle	[redacted]
3.3.10	Duration of exposure	[redacted]
3.3.11	Controls	[redacted]
3.4	**Examinations**	
3.4.1	Observations	
3.4.1.1	Clinical signs	[redacted]
3.4.1.2	Mortality	[redacted]
3.4.2	Body weight	[redacted]
3.4.3	Food consumption	[redacted]
3.4.4	Water consumption	[redacted]
3.4.5	Ophthalmoscopic examination	[redacted]
3.4.6	Haematology	[redacted]
3.4.7	Clinical Chemistry	[redacted]
3.4.8	Urinalysis	[redacted]

Section A6.3.3/02 Repeated dose toxicity (5 days)

Annex Point IIA, VI.6.3 Inhalation Rat

3.5 Sacrifice and pathology

3.5.1 Organ Weights [redacted]

3.5.2 Gross and histopathology [redacted]

3.5.3 Other examinations

3.5.4 Statistics [redacted]

3.6 Further remarks none

***4* RESULTS AND DISCUSSION**

4.1 Observations

4.1.1 Clinical signs [redacted]

4.1.2 Mortality [redacted]

4.2 Body weight gain [redacted]

4.3 Food consumption [redacted]

4.4 Water consumption [redacted]

4.5 Ophthalmoscopic examination [redacted]

4.6 Blood analysis

4.6.1 Haematology [redacted]

4.6.2 Clinical chemistry [redacted]

4.6.3 Urinalysis [redacted]

4.7 Sacrifice and pathology

4.7.1 Organ weights [redacted]

4.7.2 Gross and histopathology [redacted]

Section A6.3.3/02 Repeated dose toxicity (5 days)

Annex Point IIA, VI.6.3 **Inhalation Rat**

[redacted] *

4.8	**Other**	none

5 APPLICANT'S SUMMARY AND CONCLUSION

5.1	**Materials and methods**	[redacted]
5.2	**Results and discussion**	[redacted] *
5.3	**Conclusion**	
5.3.1	LOAEL	not relevant, dose-rangefinder
5.3.2	NOEL	not relevant, dose-rangefinder
5.3.3	Other	None
5.3.4	Reliability	[redacted]
5.3.5	Deficiencies	No

Section A6.3.3/02 Repeated dose toxicity (5 days)

Annex Point IIA, VI.6.3 Inhalation Rat

Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]
Materials and Methods	[redacted]
	[redacted]
	[redacted]
Results and discussion	[redacted]
	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	



Section A6.4.1/01 Subchronic toxicity (13 week)

Annex Point IIA, VI.6.4 **Gavage Rat**

[redacted]

			Official use only
		1 REFERENCE	
1.1	**Reference**	[redacted] (2002): Repeated Dose Toxicity 90-day Oral Toxicity Study in Rats with IPBC Technical (Protram™ 98); [redacted] 12.11.2002; [redacted]	[redacted]
1.2	**Data protection**	[redacted]	
1.2.1	Data owner	[redacted]	
1.2.2	Companies with letter of access	[redacted]	
1.2.3	Criteria for data protection	[redacted]	
		2 GUIDELINES AND QUALITY ASSURANCE	
2.1	**Guideline study**	Yes, US EPA Guideline 870.3100 (OPPTS) OECD Guideline No. 408 Directive 96/54 EEC B.26	[redacted]
2.2	**GLP**	[redacted]	
2.3	**Deviations**	No	
		3 MATERIALS AND METHODS	
3.1	**Test material**	[redacted]	
3.1.1	Lot/Batch number	[redacted]	
3.1.2	Specification	As given in section 2	
3.1.3	Purity	[redacted]	
3.1.4	Description	[redacted]	
3.1.5	Stability	[redacted]	

Section A6.4.1/01 Subchronic toxicity (13 week)

Annex Point IIA, VI.6.4 **Gavage Rat**

3.2	**Test Animals**	
3.2.1	Species	rat
3.2.2	Strain	Hsd:Sprague Dawley SD (full barrier)
3.2.3	Source	[redacted]
3.2.4	Sex	male, female
3.2.5	Age/weight at study initiation	[redacted]
3.2.6	Number of animals per group	[redacted]
3.2.7	Control animals	[redacted]
3.3	**Administration/ Exposure**	Oral
3.3.1	Duration of treatment	[redacted]
3.3.2	Frequency of exposure	[redacted]
3.3.3	Post-exposure period	[redacted]
3.3.4	Type	[redacted]
3.3.5	Concentration	[redacted]
3.3.6	Vehicle	[redacted]
3.3.7	Concentration in vehicle	[redacted]
3.3.8	Total volume applied	[redacted]
3.3.9	Controls	[redacted]
3.4	**Examinations**	
3.4.1	Observations	[redacted] *
3.4.1.1	Clinical signs	[redacted]
3.4.1.2	Mortality	[redacted]
3.4.2	Body weight	[redacted]
3.4.3	Food consumption	[redacted]
3.4.4	Water consumption	[redacted]
3.4.5	Ophthalmoscopic examination	[redacted]
3.4.6	Haematology	[redacted]

Section A6.4.1/01 Subchronic toxicity (13 week)

Annex Point IIA, VI.6.4 **Gavage Rat**

3.4.7 Clinical Chemistry

3.4.8 Urinalysis

3.5 Sacrifice and pathology

3.5.1 Organ Weights

3.5.2 Gross and histopathology

3.5.3 Other examinations

3.5.4 Statistics

3.6 Further remarks none

4 RESULTS AND DISCUSSION

4.1 Observations

4.1.1 Clinical signs



*



Section A6.4.1/01 Subchronic toxicity (13 week)

Annex Point IIA, VI.6.4 **Gavage Rat**



4.1.2 Mortality

4.2 Body weight gain

4.3 Food consumption and food conversion ratio

4.4 Ophthalmoscopic examination

4.5 Blood analysis

4.5.1 Haematology

Section A6.4.1/01 Subchronic toxicity (13 week)

Annex Point IIA, VI.6.4 **Gavage Rat**

4.5.2 Clinical chemistry



4.5.3 Urinalysis

4.6 Sacrifice and pathology

4.6.1 Organ weights



Section A6.4.1/01 Subchronic toxicity (13 week)

Annex Point IIA, VI.6.4 Gavage Rat

4.6.2 Gross and histopathology

[redacted]

4.7 Other

none

5 APPLICANT'S SUMMARY AND CONCLUSION

5.1 Materials and methods

In an 90-day gavage study, 10 rats/sex/group were treated with 0, 10, 20, 35 and 80 mg/kg bw/day according to US EPA Guideline 870.3100 (OPPTS), OECD Guideline No. 408, and Directive 96/54 EEC B.26.

5.2 Results and discussion

[redacted]

*

Section A6.4.1/01 Subchronic toxicity (13 week)

Annex Point IIA, VI.6.4 **Gavage Rat**

5.3	**Conclusion**	
5.3.1	LO(A)EL	80 mg/kg bw/day for both sexes
5.3.2	NOAEL	35 mg/kg bw/day for both sexes, based on reduced body weight and body weight gain at the next higher dose (80 mg/kg bw/day) *
5.3.3	NOEL	10 mg/kg bw/day for both sexes
5.3.4	Other	[redacted]
5.3.5	Reliability	[redacted]
5.3.6	Deficiencies	No

Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]
Materials and Methods	[redacted]
Results and discussion	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	[redacted]

[redacted]



[redacted]



Section A6.4.1/02 Subchronic toxicity (13 week)

Annex Point IIA, VI.6.4 Gavage Rat

			Official use only
		1 REFERENCE	
1.1	**Reference**	[redacted] (1984): 90-Day Subchronic Oral Toxicity Test in Rats, [redacted] 11.05.1984	[redacted]
1.2	**Data protection**	[redacted]	
1.2.1	Data owner	[redacted]	
1.2.2	Companies with letter of access	[redacted]	
1.2.3	Criteria for data protection	[redacted]	
		2 GUIDELINES AND QUALITY ASSURANCE	
2.1	**Guideline study**	No, however, methods used are comparable to OECD Guideline No. 408	[redacted]
2.2	**GLP**	[redacted]	*
2.3	**Deviations**	to OECD Guideline No. 408 - no haematological parameter for blood clotting - determination of triglycerides, cholesterol was not performed	
		3 MATERIALS AND METHODS	
3.1	**Test material**	[redacted]	
3.1.1	Lot/Batch number	[redacted]	
3.1.2	Specification	As given in section 2	
3.1.2.1	Description	[redacted]	
3.1.2.2	Purity	[redacted]	
3.1.2.3	Stability	[redacted]	
3.2	**Test Animals**		
3.2.1	Species	rat	
3.2.2	Strain	Sprague Dawley	
3.2.3	Source	[redacted]	
3.2.4	Sex	male, female	
3.2.5	Age/weight at study initiation	[redacted]	
3.2.6	Number of animals	[redacted]	

Section A6.4.1/02 Subchronic toxicity (13 week)

Annex Point IIA, VI.6.4 Gavage Rat

	per group	
3.2.7	Control animals	
3.3	**Administration/ Exposure**	Oral
3.3.1	Duration of treatment	
3.3.2	Frequency of exposure	
3.3.3	Post-exposure period	
3.3.4	Type	
3.3.5	Concentration	
3.3.6	Vehicle	
3.3.7	Concentration in vehicle	
3.3.8	Total volume applied	
3.3.8.1	Controls	
3.4	**Examinations**	
3.4.1	Observations	
3.4.1.1	Clinical signs	
3.4.1.2	Mortality	
3.4.2	Body weight	
3.4.3	Food consumption	
3.4.4	Water consumption	
3.4.5	Ophthalmoscopic examination	
3.4.6	Haematology	
3.4.7	Clinical Chemistry	
3.4.8	Urinalysis	

Section A6.4.1/02 Subchronic toxicity (13 week)

Annex Point IIA, VI.6.4 **Gavage Rat**

3.5 Sacrifice and pathology

3.5.1 Organ Weights

3.5.2 Gross and histopathology

3.5.3 Other examinations

3.5.4 Statistics

3.6 Further remarks none

4 RESULTS AND DISCUSSION

4.1 Observations

4.1.1 Clinical signs

4.1.2 Mortality

4.2 Body weight gain

4.3 Food consumption

4.4 Ophthalmoscopic examination

4.5 Blood analysis

4.5.1 Haematology

4.5.2 Clinical chemistry

Section A6.4.1/02 Subchronic toxicity (13 week)

Annex Point IIA, VI.6.4 **Gavage Rat**

4.6 Sacrifice and pathology

4.6.1 Organ weights

[redacted]

4.6.2 Gross and histopathology

[redacted]

[redacted] *

4.7 Other

none

5 APPLICANT'S SUMMARY AND CONCLUSION

5.1 Materials and methods

In an 90-day gavage study, 10 rats/sex/group were treated with 0, 20, 50 and 125 mg/kg bw/day, 5 days per week (comparable to OECD Guideline No. 408).

5.2 Results and discussion

[redacted]

Section A6.4.1/02 Subchronic toxicity (13 week)

Annex Point IIA, VI.6.4 **Gavage Rat**

[redacted]

5.3 Conclusion

5.3.1	LO(A)EL	50 mg/kg bw/day for both sexes
5.3.2	NO(A)EL	20 mg/kg bw/day for both sexes, based on clinical signs (burrowing behavior). *
5.3.3	Other	[redacted]
5.3.4	Reliability	[redacted]
5.3.5	Deficiencies	No

Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]
Materials and Methods	[redacted]
Results and discussion	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	[redacted]



Section A6.4.1/03 Repeated dose toxicity (13 week)

Annex Point IIA, VI.6.4 Feeding rabbit

1 REFERENCE

Official use only

1.1	**Reference**	[redacted]. (1997): A Subchronic (3-Month) Toxicity Study of Troysan Polyphase P100 in the Rabbit via Dietary Administration; [redacted] 13.02.1997; [redacted]
1.2	**Data protection**	[redacted]
1.2.1	Data owner	[redacted]
1.2.2	Companies with letter of access	[redacted]
1.2.3	Criteria for data protection	[redacted]

2 GUIDELINES AND QUALITY ASSURANCE

2.1	**Guideline study**	Yes, OECD guideline for testing of chemicals, No. 409 „Subchronic Oral Toxicity – Non-rodent: 90-Day Study" (Adopted 1981)
2.2	**GLP**	[redacted]
2.3	**Deviations**	Yes from current OECD 409 (adopted 1998), One of the four groups consisted of 6 males and 4 females (recommended 5 animals per sex). Urinalysis was not conducted. Gall bladder ovaries, uterus, thymus, spleen, brain, and heart were not weighed. Prostate was not examined by histopathology. *

3 MATERIALS AND METHODS

3.1	**Test material**	[redacted]
3.1.1	Lot/Batch number	[redacted]
3.1.2	Specification	As given in section 2
3.1.3	Purity	[redacted]
3.1.4	Description	[redacted]
3.1.5	Stability	[redacted]

Section A6.4.1/03 Repeated dose toxicity (13 week)

Annex Point IIA, VI.6.4 Feeding rabbit

3.2	**Test Animals**	
3.2.1	Species	rabbit
3.2.2	Strain	New Zealand White
3.2.3	Source	[redacted]
3.2.4	Sex	male, female
3.2.5	Age/weight at study initiation	[redacted]
3.2.6	Number of animals per group	[redacted]
3.2.7	Control animals	[redacted]
3.3	**Administration/ Exposure**	Oral
3.3.1	Duration of treatment	[redacted]
3.3.2	Frequency of exposure	[redacted]
3.3.3	Post-exposure period	[redacted]
3.3.4	Type	[redacted]
3.3.5	Concentration	[redacted]
		[redacted]
3.3.6	Vehicle	[redacted]
3.3.7	Concentration in vehicle	[redacted]
3.3.8	Total volume applied	[redacted]
3.3.8.1	Controls	[redacted]
3.4	**Examinations**	
3.4.1	Observations	
3.4.1.1	Clinical signs	[redacted]
3.4.1.2	Mortality	[redacted]
3.4.2	Body weight	[redacted]
3.4.3	Food consumption	[redacted]
3.4.4	Water consumption	[redacted]
3.4.5	Ophthalmoscopic examination	[redacted]

Section A6.4.1/03 Repeated dose toxicity (13 week)

Annex Point IIA, VI.6.4 **Feeding rabbit**

3.4.6 Haematology

3.4.7 Clinical Chemistry

3.4.8 Urinalysis

3.5 Sacrifice and pathology

3.5.1 Organ Weights

3.5.2 Gross and histopathology

3.5.3 Other examinations

3.5.4 Statistics

3.6 Further remarks none

4 RESULTS AND DISCUSSION

4.1 Observations

4.1.1 Clinical signs

4.1.2 Mortality

Section A6.4.1/03 Repeated dose toxicity (13 week)

Annex Point IIA, VI.6.4 **Feeding rabbit**

4.2 Body weight gain

4.3 Food consumption and compound intake

4.4 Ophthalmoscopic examination

4.5 Blood analysis

4.5.1 Haematology



4.5.2 Clinical chemistry



Section A6.4.1/03 Repeated dose toxicity (13 week)

Annex Point IIA, VI.6.4 **Feeding rabbit**

[redacted]

4.5.3 Urinalysis [redacted]

4.6 Sacrifice and pathology

4.6.1 Organ weights [redacted]

4.6.2 Gross and histopathology [redacted]

4.7 Other none

Section A6.4.1/03 Repeated dose toxicity (13 week)

Annex Point IIA, VI.6.4 **Feeding rabbit**

5 APPLICANT'S SUMMARY AND CONCLUSION

5.1 Materials and methods

[redacted] *

5.2 Results and discussion

[redacted] *

5.3 Conclusion

5.3.1 LOAEL: 2000 ppm for both sexes, equivalent to 75 mg/kg bw/day

5.3.2 NOEL: 500 ppm for both sexes, equivalent to 13 mg/kg bw/day (based on histological findings finaly granlar cytoplasm with bron pigment in liver at 2000 and 4000 ppm in both sexes)

5.3.3 Other: [redacted]

5.3.4 Reliability: [redacted]

5.3.5 Deficiencies: No

Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]
Materials and Methods	[redacted]

Section A6.4.1/03 Repeated dose toxicity (13 week)

Annex Point IIA, VI.6.4 **Feeding rabbit**

Results and discussion	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	



Section A6.4.2/01 Subchronic toxicity (13-week)

Annex Point IIA, VI.6.4 **Dermal, Rat**

			Official use only
		1 REFERENCE	
1.1	**Reference**	[redacted] (1991): 91-Day Dermal Toxicity Study in Rat with Troysan Polyphase P-100; [redacted] 06.12.1991 [redacted]	[redacted]
1.2	**Data protection**	[redacted]	
1.2.1	Data owner	[redacted]	
1.2.2	Companies with letter of access	[redacted]	
1.2.3	Criteria for data protection	[redacted]	
		2 GUIDELINES AND QUALITY ASSURANCE	
2.1	**Guideline study**	Yes, US EPA guideline 82-3 which is in compliance with OECD 411	[redacted]
2.2	**GLP**	[redacted]	
2.3	**Deviations**	Yes, salivary glands were not preserved as required by OECD 411	
		3 MATERIALS AND METHODS	
3.1	**Test material**	[redacted]	
3.1.1	Lot/Batch number	[redacted]	
3.1.2	Specification	As given in section 2. The purity of the test substance was slightly lower than the specification given in Section 2. Thios does not influence the integrity of the study	
3.1.3	Purity	[redacted]	
3.1.4	Description	[redacted]	
3.1.5	Stability	[redacted]	
3.2	**Test Animals**		
3.2.1	Species	Rat	
3.2.2	Strain	Sprague-Dawley Crl:CD® BR VAF/Plus®	
3.2.3	Source	[redacted]	
3.2.4	Sex	male, female	
3.2.5	Age/weight at study initiation	[redacted]	

Section A6.4.2/01 Subchronic toxicity (13-week)

Annex Point IIA, VI.6.4 Dermal, Rat

3.2.6	Number of animals per group	[redacted]
3.2.7	Control animals	[redacted]
3.3	**Administration/ Exposure**	dermal
3.3.1	Duration of treatment	13 weeks
3.3.2	Frequency of exposure	[redacted]
3.3.3	Post-exposure period	[redacted]
3.3.4	Area covered	[redacted]
3.3.5	Occlusion	[redacted]
3.3.6	Vehicle	[redacted]
3.3.7	Concentration in vehicle	[redacted]
3.3.8	Total volume applied	[redacted]
3.3.9	Duration of exposure	[redacted]
3.3.10	Removal of test substance	[redacted]
3.3.11	Controls	[redacted]
3.4	**Examinations**	
3.4.1	Observations	
3.4.1.1	Clinical signs	[redacted]
3.4.1.2	Mortality	[redacted]
3.4.2	Body weight	[redacted]
3.4.3	Food consumption	[redacted]
3.4.4	Water consumption	[redacted]
3.4.5	Ophthalmoscopic examination	[redacted]
3.4.6	Haematology	[redacted]

Section A6.4.2/01 Subchronic toxicity (13-week)

Annex Point IIA, VI.6.4 **Dermal, Rat**

3.4.7 Clinical Chemistry



3.4.8 Urinalysis

3.5 Sacrifice and pathology

3.5.1 Organ Weights

3.5.2 Gross and histopathology



3.5.3 Other examinations

3.5.4 Statistics

3.6 Further remarks none

4 RESULTS AND DISCUSSION

4.1 Observations

4.1.1 Clinical signs



4.1.2 Mortality

4.1.3 Dermal observations



Section A6.4.2/01 Subchronic toxicity (13-week)

Annex Point IIA, VI.6.4 **Dermal, Rat**



4.2 Body weight gain

4.3 Food consumption

4.4 Ophthalmoscopic examination

4.5 Blood analysis

4.5.1 Haematology

4.5.2 Clinical chemistry

Section A6.4.2/01 Subchronic toxicity (13-week)

Annex Point IIA, VI.6.4 **Dermal, Rat**

4.5.3	Urinalysis	[redacted]
4.6	**Sacrifice and pathology**	
4.6.1	Organ weights	[redacted]
4.6.2	Gross and histopathology	[redacted] *
4.7	**Other**	none

5 APPLICANT'S SUMMARY AND CONCLUSION

5.1 Materials and methods

In compliance with OECD 411 guideline and according to US EPA guideline 82-3, 10 animals/sex/dose were dermally treated with 0, 50, 200, and 500 mg/kg bw/day for 13 weeks. Animals were treated 5 days per week for 6 hours the day.

Section A6.4.2/01 Subchronic toxicity (13-week)

Annex Point IIA, VI.6.4 **Dermal, Rat**

5.2	Results and discussion		*
5.3	Conclusion		
5.3.1	LO(A)EL	500 mg/kg bw/day for both sexes	*
5.3.2	NOAEL	The systemic NOAEL of this study is considered to be 200 mg/kg bw/day based on effects persistent irritation of the treated skin observed at 500 mg/kg bw/day. Hyperkeratosis observed at 200 mg/kg bw/day was mild and not considered to be reversible.	*
5.3.3	NOEL	50 mg/kg bw/day	
5.3.4	Other	none	
5.3.5	Reliability	[redacted]	
5.3.6	Deficiencies	No	

Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]
Materials and Methods	[redacted]
Results and discussion	[redacted]
Conclusion	[redacted]
Reliability	[redacted]

Section A6.4.2/01 Subchronic toxicity (13-week)

Annex Point IIA, VI.6.4 Dermal, Rat

Acceptability	[redacted]
Remarks	

[redacted]



Section A6.4.3/01 Subchronic toxicity (13 weeks)

Annex Point IIA, VI.6.4 Inhalation, Rat

			Official use only
		1 REFERENCE	
1.1	**Reference**	[redacted] (1994): 13-week inhalation toxicity study in rats; [redacted]	[redacted]
1.2	**Data protection**	[redacted]	
1.2.1	Data owner	[redacted]	
1.2.2	Companies with letter of access	[redacted]	
1.2.3	Criteria for data protection	[redacted]	
		2 GUIDELINES AND QUALITY ASSURANCE	
2.1	**Guideline study**	A specific guideline in not mentioned. The method used is comparable to OECD guideline 413 adopted 1981.	[redacted]
2.2	**GLP**	[redacted]	
2.3	**Deviations**	Yes, adrenals were not weighed	
		3 MATERIALS AND METHODS	
3.1	**Test material**	[redacted]	
3.1.1	Lot/Batch number	[redacted]	
3.1.2	Specification	The purity of the test material is slightly lower than the specifications given in section 2. This does not influence the integrity of the study.	
3.1.3	Purity	[redacted]	
3.1.4	Description	[redacted]	
3.1.5	Stability	[redacted]	
3.2	**Test Animals**		
3.2.1	Species	rat	
3.2.2	Strain	Sprague Dawley Crl:CD BR	
3.2.3	Source	[redacted]	
3.2.4	Sex	Male, female	

Section A6.4.3/01 Subchronic toxicity (13 weeks)

Annex Point IIA, VI.6.4 Inhalation, Rat

3.2.5	Age/weight at study initiation	
3.2.6	Number of animals per group	
3.2.7	Control animals	
3.3	**Administration/ Exposure**	
3.3.1	Duration of treatment	
3.3.2	Frequency of exposure	
3.3.3	Post-exposure period	
3.3.4	Concentrations	



Section A6.4.3/01 Subchronic toxicity (13 weeks)

Annex Point IIA, VI.6.4 Inhalation, Rat

3.3.5	Particle size	
3.3.6	Type or preparation of particles	
3.3.7	Type of exposure	
3.3.8	Vehicle	
3.3.9	Concentration in vehicle	
3.3.10	Duration of exposure	
3.3.11	Controls	
3.4	**Examinations**	
3.4.1	Observations	
3.4.1.1	Clinical signs	
3.4.1.2	Mortality	
3.4.2	Body weight	
3.4.3	Food consumption	
3.4.4	Water consumption	
3.4.5	Ophthalmoscopic examination	
3.4.6	Haematology	
3.4.7	Clinical Chemistry	

Section A6.4.3/01 Subchronic toxicity (13 weeks)

Annex Point IIA, VI.6.4 **Inhalation, Rat**

3.4.8 Urinalysis

3.5 Sacrifice and pathology

3.5.1 Organ Weights

3.5.2 Gross and histopathology



3.5.3 Other examinations

3.5.4 Statistics

3.6 Further remarks

Section A6.4.3/01 Subchronic toxicity (13 weeks)

Annex Point IIA, VI.6.4 Inhalation, Rat

[redacted]

4 RESULTS AND DISCUSSION

4.1 Observations

4.1.1 Clinical signs

[redacted] *

4.1.2 Mortality

[redacted]

4.2 Body weight gain

[redacted]

4.3 Food consumption

[redacted]

4.4 Ophthalmoscopic examination

[redacted]

4.5 Blood analysis

4.5.1 Haematology

[redacted]

4.5.2 Clinical chemistry

[redacted]

Section A6.4.3/01 Subchronic toxicity (13 weeks)

Annex Point IIA, VI.6.4 **Inhalation, Rat**



4.5.3 Urinalysis

4.6 Sacrifice and

Section A6.4.3/01 Subchronic toxicity (13 weeks)

Annex Point IIA, VI.6.4 Inhalation, Rat

	pathology
4.6.1	Organ weights
4.6.2	Gross and histopathology



*

Section A6.4.3/01 Subchronic toxicity (13 weeks)

Annex Point IIA, VI.6.4 Inhalation, Rat

[redacted]

4.7 Other

none

5 APPLICANT'S SUMMARY AND CONCLUSION

5.1 Materials and methods

[redacted] However, the method used is in compliance with current OECD 413 (Subchronic Inhalation Toxicity: 90-day Study) adopted 1981. Deviations did not influence the outcome of the study.

[redacted]

5.2 Results and discussion

[redacted] *

5.3 Conclusion

5.3.1 LO(A)EL

The LOEL of this study was considered to be 6.7 mg/m^3 (high dose). This LOEL based on histopathological findings in larynx in rats.

5.3.2 NO(A)EL

The NOAEL of this 90-day inhalation toxicity study was considered to be 1.16 mg/m^3.

Section A6.4.3/01 Subchronic toxicity (13 weeks)

Annex Point IIA, VI.6.4 Inhalation, Rat

5.3.3	Other	None
5.3.4	Reliability	[redacted]
5.3.5	Deficiencies	No

Use separate "evaluation boxes" to provide transparency as to the comments and views submitted

EVALUATION BY RAPPORTEUR MEMBER STATE

Date [redacted]

Materials and Methods [redacted]

Results and discussion [redacted]

Conclusion [redacted]

Reliability [redacted]

Acceptability [redacted]

Remarks [redacted]

[redacted]



[redacted]



Section A6.6.1/01 Genotoxicity *in vitro*
Annex Point IIA, VI.6.6.1 Gene mutation in bacteria

[redacted]

			Official use only
		1 REFERENCE	
1.1	**Reference**	Herbold, B. (2001): Preventol MP 100 – Salmonella/Microsome Test, Plate Incubation and Preincubation Method [redacted] 26.03.2001	[redacted]
1.2	**Data protection**	[redacted]	
1.2.1	Data owner	[redacted]	
1.2.2	Companies with letter of access	[redacted]	
1.2.3	Criteria for data protection	[redacted]	
		2 GUIDELINES AND QUALITY ASSURANCE	
2.1	**Guideline study**	[redacted] EC guideline B.14., OECD guideline 471 (21.07.1997), OPPTS 870.5100	
2.2	**GLP**	[redacted]	
2.3	**Deviations**	No	
		3 MATERIALS AND METHODS	
3.1	**Test material**	[redacted]	
3.1.1	Lot/Batch number	[redacted]	
3.1.2	Specification	As given in section 2	
3.1.3	Purity	[redacted]	
3.1.4	Description	[redacted]	
3.1.5	Stability	[redacted]	
3.2	**Study Type**	Bacterial reverse mutation test	
3.2.1	Organism/cell type	*S. typhimurium*: TA 1535, TA 100, TA 1537, TA 98, TA 102	
3.2.2	Deficiencies / Proficiencies	[redacted]	
3.2.3	Metabolic activation system	[redacted]	

Section A6.6.1/01 Genotoxicity *in vitro*

Annex Point IIA, VI.6.6.1 Gene mutation in bacteria

3.2.4	Positive control	[redacted]
3.3	**Administration / Exposure; Application of test substance**	
3.3.1	Concentrations	[redacted]
3.3.2	Way of application	[redacted]
3.3.3	Pre-incubation time	[redacted]
3.4	**Examinations**	[redacted]
3.4.1	Number of cells evaluated	[redacted]
		4 RESULTS AND DISCUSSION
4.1	**Genotoxicity**	
4.1.1	without metabolic activation	[redacted]
4.1.2	with metabolic activation	[redacted]
4.2	**Cytotoxicity**	[redacted]

Section A6.6.1/01 Genotoxicity *in vitro*

Annex Point IIA, VI.6.6.1 Gene mutation in bacteria

5 APPLICANT'S SUMMARY AND CONCLUSION

5.1 Materials and methods

This study was performed to assess the potential of IPBC to induce gene mutations in bacteria (OECD guideline 471).

[redacted]

5.2 Results and discussion

[redacted]

5.3 Conclusion

IPBC was considered to be non-mutagenic without and with S9 mix in the plate incorporation as well as in the preincubation modification of the Salmonella/microsome test.

5.3.1 Reliability [redacted]

5.3.2 Deficiencies [redacted]

Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]
Materials and Methods	[redacted]
Results and discussion	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	

[redacted]



[redacted]

[redacted]	[redacted]				
[redacted]					
	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]					
	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]
[redacted]	[redacted]	[redacted]	[redacted]	[redacted]	[redacted]

Section A6.6.2/01 Genotoxicity *in vitro*

Annex Point IIA, VI.6.6.2 Cytogenicity in Mammalian Cells (Chromosome Aberration in V79 cells)

		2 REFERENCE	Official use only
1.1	**Reference**	[redacted] (2001): In vitro Chromosome Aberration Test with Chinese Hamster V79 Cells; [redacted] 15.03.2001 [redacted]	[redacted]
1.2	**Data protection**	[redacted]	
1.2.1	Data owner	[redacted]	
1.2.2	Companies with letter of access	[redacted]	
1.2.3	Criteria for data protection	[redacted]	
		2 GUIDELINES AND QUALITY ASSURANCE	
2.1	**Guideline study**	[redacted] EC guideline B.10., OECD guideline 473 (adopted 21.07.1997) [redacted]	
2.2	**GLP**	[redacted]	
2.3	**Deviations**	No	
		3 MATERIALS AND METHODS	
3.1	**Test material**	[redacted]	
3.1.1	Lot/Batch number	[redacted]	
3.1.2	Specification	As given in section 2	
3.1.3	Purity	[redacted]	
3.1.4	Description	[redacted]	
3.1.5	Stability	[redacted]	
3.2	**Study Type**	In Vitro mammalian chromosome aberration test	
3.2.1	Organism/cell type	Chinese hamster lung fibroblasts (V79)	
3.2.2	Deficiencies / Proficiencies	[redacted]	
3.2.3	Metabolic activation system	[redacted]	
3.2.4	Positive control	[redacted]	

Section A6.6.2/01 Genotoxicity *in vitro*

Annex Point IIA, VI.6.6.2 **Cytogenicity in Mammalian Cells (Chromosome Aberration in V79 cells)**

3.3	**Administration / Exposure; Application of test substance**	
3.3.1	Concentrations	[redacted]
3.3.2	Way of application	[redacted]
3.3.3	Pre-incubation time	[redacted]
3.4	**Examinations**	
3.4.1	Number of cells evaluated	[redacted]

4 RESULTS AND DISCUSSION

4.1	**Genotoxicity**	
4.1.1	without metabolic activation	[redacted]
4.1.2	with metabolic activation	[redacted]
4.2	**Cytotoxicity**	[redacted] *

Section A6.6.2/01 Genotoxicity *in vitro*

Annex Point IIA, VI.6.6.2 Cytogenicity in Mammalian Cells (Chromosome Aberration in V79 cells)

5 APPLICANT'S SUMMARY AND CONCLUSION

5.1 Materials and methods

This study was performed to assess the effects of IPBC on cytogenicity *in vitro* (OECD guideline 473).

[redacted]

5.2 Results and discussion

[redacted] *

With or without metabolic activation, no biologically relevant and statistically significant increases of metaphases with aberrations were detected after a treatment time of 4 h and total culture times of 18 or 30 h.

[redacted]

5.3 Conclusion

IPBC was considered to be not clastogenic for mammalian cells *in vitro*. *

5.3.1 Reliability [redacted]

5.3.2 Deficiencies [redacted]

Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]

Section A6.6.2/01 Genotoxicity *in vitro*

Annex Point IIA, VI.6.6.2 **Cytogenicity in Mammalian Cells (Chromosome Aberration in V79 cells)**

Materials and Methods	[redacted]
Results and discussion	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	

[redacted]



[redacted]

[redacted]



[redacted]

[redacted]

[redacted]

[redacted]

[redacted]

[redacted]



[redacted]

Section A6.6.3/01 Genotoxicity *in vitro*

Annex Point IIA, VI.6.6.3 Gene Mutation in Mammalian Cells (HPRT, V79)

[redacted]

		3 REFERENCE	Official use only
1.1	**Reference**	[redacted] (2001): Preventol MP 100 – V79/HPRT-Test in vitro for the Detection of Induced Forward Mutations; [redacted] 29.06.2001	[redacted]
1.2	**Data protection**	[redacted]	
1.2.1	Data owner	[redacted]	
1.2.2	Companies with letter of access	[redacted]	
1.2.3	Criteria for data protection	[redacted]	
		2 GUIDELINES AND QUALITY ASSURANCE	
2.1	**Guideline study**	[redacted] EEC Directive 88/302/EEC (Mutagenicity, in vitro Mammalian Cell – Gene Mutation Test); OECD guideline 476; OPPTS 870.5300	[redacted]
2.2	**GLP**	[redacted]	
2.3	**Deviations**	[redacted]	
		3 MATERIALS AND METHODS	
3.1	**Test material**	[redacted]	
3.1.1	Lot/Batch number	[redacted]	
3.1.2	Specification	As given in section 2	
3.1.3	Purity	[redacted]	
3.1.4	Description	[redacted]	
3.1.5	Stability	[redacted]	
3.2	**Study Type**	In vitro mammalian cell gene mutation test, HPRT	
3.2.1	Organism/cell type	Chinese hamster lung fibroblasts (V79)	
3.2.2	Deficiencies / Proficiencies	[redacted]	
3.2.3	Metabolic activation system	[redacted]	

Section A6.6.3/01 Genotoxicity *in vitro*

Annex Point IIA, VI.6.6.3 Gene Mutation in Mammalian Cells (HPRT, V79)

3.2.4	Positive control	[redacted]
3.3	**Administration / Exposure; Application of test substance**	
3.3.1	Concentrations	[redacted]
3.3.2	Way of application	[redacted]
3.3.3	Pre-incubation time	[redacted]
3.4	**Examinations**	
3.4.1	Number of cells evaluated	[redacted]
	4 RESULTS AND DISCUSSION	
4.1	**Genotoxicity**	
4.1.1	without metabolic activation	[redacted]
4.1.2	with metabolic activation	[redacted]
4.2	**Cytotoxicity**	[redacted]

Section A6.6.3/01 Genotoxicity *in vitro*

Annex Point IIA, VI.6.6.3 Gene Mutation in Mammalian Cells (HPRT, V79)

5 APPLICANT'S SUMMARY AND CONCLUSION

5.1 Materials and methods

This study was performed to assess the mutagenic effects of IPBC *in vitro* on mammalian cells (V79, OECD guideline 476).

[redacted]

5.2 Results and discussion

[redacted]

5.3 Conclusion

IPBC is considered to be non-mutagenic in the V79/HPRT forward mutation assay, both with and without metabolic activation.

5.3.1 Reliability [redacted]

5.3.2 Deficiencies [redacted]

Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]
Materials and Methods	[redacted]
Results and discussion	[redacted]
Conclusion	[redacted]
Reliability	[redacted]

Section A6.6.3/01 Genotoxicity *in vitro*

Annex Point IIA, VI.6.6.3 Gene Mutation in Mammalian Cells (HPRT, V79)

Acceptability	[redacted]
Remarks	[redacted]



[redacted]

[redacted]

Section A6.6.4/01 Genotoxicity *in vivo*

Annex Point IIA, VI.6.6.4 Mammalian Erythrocyte Micronucleus Test, Mice

[redacted]

			Official use only
		1 REFERENCE	
1.1	**Reference**	[redacted] (1993): Micronucleus cytogenetic assay in mice; [redacted] 10.05.93	[redacted]
1.2	**Data protection**	[redacted]	
1.2.1	Data owner	[redacted]	
1.2.2	Companies with letter of access	[redacted]	
1.2.3	Criteria for data protection	[redacted]	
		2 GUIDELINES AND QUALITY ASSURANCE	
2.1	**Guideline study**	[redacted] 40 CFR Part 158, FIFRA, Section 158.340, Guideline 84-2; the method used is comparable to OECD guideline 474	[redacted]
2.2	**GLP**	[redacted]	
2.3	**Deviations**	Yes, the number of polychromatic erythrocytes counted per animal was 1000 instead of 2000 as required in the OECD 474. However, this deviation is not considered to have influenced the outcome of the study.	
		3 MATERIALS AND METHODS	
3.1	**Test material**	[redacted]	
3.1.1	Lot/Batch number	[redacted]	
3.1.2	Specification	The purity of the test substance was slightly lower than the specification given in section 2. This does not influence the integrity of the study.	
3.1.3	Purity	[redacted]	
3.1.4	Description	[redacted]	
3.1.5	Stability	[redacted]	
3.1.6	Maximum tolerable dose	[redacted]	
3.2	**Test Animals**		
3.2.1	Species	Mouse	
3.2.2	Strain	ICR	
3.2.3	Source	[redacted]	
3.2.4	Sex	Male and female	

Section A6.6.4/01 Genotoxicity *in vivo*

Annex Point IIA, VI.6.6.4 Mammalian Erythrocyte Micronucleus Test, Mice

3.2.5	Age/weight at study initiation	[redacted]
3.2.6	Number of animals per group	[redacted]
3.2.7	Control animals	[redacted]
3.3	**Administration/ Exposure**	intraperitoneal
3.3.1	Number of applications	[redacted]
3.3.2	Post-exposure period	[redacted]
3.3.3	Vehicle	[redacted]
3.3.4	Concentration in vehicle	[redacted]
3.3.5	Total volume applied	[redacted]
3.3.6	dose applied	[redacted]
3.3.7	Substance used as Positive Control	[redacted]
3.3.8	Controls	[redacted]
3.4	**Examinations**	
3.4.1	Clinical signs	[redacted]
3.4.2	Tissue	[redacted]

Section A6.6.4/01 Genotoxicity *in vivo*

Annex Point IIA, VI.6.6.4 Mammalian Erythrocyte Micronucleus Test, Mice

4 RESULTS AND DISCUSSION

4.1	Clinical signs	[redacted]
4.2	Haematology / Tissue examination	[redacted]
4.3	Genotoxicity	[redacted]
4.4	Other	[redacted]

5 APPLICANT'S SUMMARY AND CONCLUSION

5.1	Materials and methods	This in vivo study was performed to assess the mutagenic effects of IPBC on bone marrow and erythrocytes of mice (40 CFR Part 158, FIFRA, Section 158.340, Guideline 84-2). [redacted]
5.2	Results and discussion	[redacted]
5.3	Conclusion	Under the conditions of the assay described in this report, IPBC did not induce a significant increase in the incidence of micronucleated polychromatic erythrocytes in bone marrow and was concluded to be negative in the micronucleus test using male and female ICR mice.
5.3.1	Reliability	[redacted]
5.3.2	Deficiencies	[redacted]

Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]
Materials and Methods	[redacted]
Results and discussion	[redacted]

Section A6.6.4/01 Genotoxicity *in vivo*

Annex Point IIA, VI.6.6.4 Mammalian Erythrocyte Micronucleus Test, Mice

Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
Remarks	

[redacted]

Section A6.6.5 Annex Point IIA, VI.6.6.5	Genotoxicity *in vivo* (e.g. DNA damage)	
	JUSTIFICATION FOR NON-SUBMISSION OF DATA	Official use only
Other existing data [ ]	**Technically not feasible** [ ] **Scientifically unjustified** [X]	
Limited exposure [ ]	**Other justification** [ ]	
Detailed justification:	The submission of studies investigating DNA damage *in vivo* is only required if genotoxicity was demonstrated *in vitro*. However, genotoxicity testing *in vitro* demonstrated the absence of mutagenic or cytogenic effects. Thus, the submission of further genotoxicity studies *in vivo* is not required.	
	Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted	
	EVALUATION BY RAPPORTEUR MEMBER STATE	
Date	[redacted]	
Evaluation of applicant's justification	[redacted]	
Conclusion	[redacted]	
Remarks		

Section A6.6.6 Annex Point IIA, VI.6.6.6	Germ cell effects	
	JUSTIFICATION FOR NON-SUBMISSION OF DATA	Official use only
Other existing data [ ]	**Technically not feasible** [ ] **Scientifically unjustified** [X]	
Limited exposure [ ]	**Other justification** [ ]	
Detailed justification:	The submission of a study testing germ cell effects is only required if genotoxicity was demonstrated *in vitro* and *in vivo*. However, genotoxicity tests *in vitro* and *in vivo* with IPBC demonstrated the absence of mutagenic or cytogenic effects. Thus, the submission of a study investigating germ cell effects is not required.	
	Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted	
	EVALUATION BY RAPPORTEUR MEMBER STATE	
Date	[redacted]	
Evaluation of applicant's justification	[redacted]	
Conclusion	[redacted]	
Remarks		

Section A6.7 Annex Point IIA, VI.6.6.7	Further genotoxicity testing	
	JUSTIFICATION FOR NON-SUBMISSION OF DATA	Official use only
Other existing data [ ]	**Technically not feasible** [ ] **Scientifically unjustified** [X]	
Limited exposure [ ]	**Other justification** [ ]	
Detailed justification:	The submission of further studies on genotoxicity is only required if metabolites of concern are formed in mammals [redacted]	
	Evaluation by Competent Authorities	
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted	
	EVALUATION BY RAPPORTEUR MEMBER STATE	
Date	[redacted]	
Evaluation of applicant's justification	[redacted]	
Conclusion	[redacted]	
Remarks		

Section A6.7/01/02/03 Chronic Toxicity/Carcinogenicity (104 weeks)
Annex Point IIA, VI.6.7 Feeding Study in Rats

		1 REFERENCE	Official use only
1.1	Reference	A6.7/01 [redacted] (1989): 3-Iodo-2-Propynyl Butyl Carbamate (IPBC) – 104 Week Dietary Carcinogenicity Study in Rats [redacted] 21.03.1989 [redacted] A6.7/02: [redacted] (1988): 3-Iodo-2-Propynyl Butyl Carbamate (IPBC) – Chronic Dietary Toxicity Study in Rats [redacted]; 18.03.1988 [redacted] A6.7/03: [redacted]. (1995): Review and Interpretation of Selected Thyroid and Forestomach Lesions in the Carcinogenicity Study of 3-Iodo-2-Propynyl Butyl Carbamate (IPBC) in Sprague-Dawley Rats [redacted] 15.06.1995 [redacted] A6.3.1/03: [redacted] (1986): Establishment of Methodology and the Routine Analysis of Iodopropynylbutyl carbamate in Diets prepared for a 4 Week Dose Range Finding Study in the Rat [redacted] 01.09.1986	[redacted]
1.2	Data protection	[redacted]	
1.2.1	Data owner	[redacted]	
1.2.2	Companies with letter of access	[redacted]	
1.2.3	Criteria for data protection	[redacted]	
		2 GUIDELINES AND QUALITY ASSURANCE	
2.1	Guideline study	A6.7/01 and A6.7/02: Yes [redacted] EPA Pesticide Assessment Guidelines F, Subdivision 83-5 which is comparable to OECD guideline 453 A6.7/03: not applicable	[redacted]
2.2	GLP	[redacted]	
2.3	Deviations	A6.7/01 and A6.7/02: Yes, Individual body weight of the animals designated for the interim kill after one year are not given. Haematology, clinical chemistry, and urinalysis were not performed after 18 months. Only 10 instead of 20 animals per sex and group were bleed. Haematology, clinical chemistry, and urinalysis were not performed after 18 months. A6.7/03: not applicable	*

Section A6.7/01/02/03 Chronic Toxicity/Carcinogenicity (104 weeks)
Annex Point IIA, VI.6.7 Feeding Study in Rats

3 MATERIALS AND METHODS

[redacted]

3.1	**Test material**	[redacted]
3.1.1	Lot/Batch number	[redacted]
3.1.2	Specification	The purity of the test substance was slightly lower than the specification given in section 2. This does not influence the integrity of the study.
3.1.3	Purity	[redacted]
3.1.4	Description	[redacted]
3.1.5	Stability	[redacted]
3.2	**Test Animals**	
3.2.1	Species	Rats
3.2.2	Strain	Sprague-Dawley
3.2.3	Source	[redacted]
3.2.4	Sex	male, female
3.2.5	Age/weight at study initiation	[redacted]
3.2.6	Number of animals per group	[redacted]
3.2.6.1	at interim sacrifice	[redacted]
3.2.6.2	at terminal sacrifice	[redacted]
3.2.7	Control animals	[redacted]
3.3	**Administration/ Exposure**	[redacted]
3.3.1	Duration of treatment	[redacted]
3.3.2	Interim sacrifice(s)	[redacted]
3.3.3	Final sacrifice	[redacted]
3.3.4	Frequency of exposure	[redacted]
3.3.5	Postexposure period	[redacted]
3.3.6	Type	[redacted]
3.3.7	Dose	[redacted]
3.3.8	Vehicle	[redacted]
3.3.9	Concentration in vehicle	[redacted] *

Section A6.7/01/02/03 **Chronic Toxicity/Carcinogenicity (104 weeks)**

Annex Point IIA, VI.6.7 **Feeding Study in Rats**

3.3.10	Total volume applied	[redacted]
3.3.11	Controls	[redacted]
3.4	**Examinations**	
3.4.1	Clinical signs	[redacted]
3.4.2	Palpable masses	[redacted]
3.4.3	Mortality	[redacted]
3.4.4	Body weight	[redacted]
3.4.5	Food consumption	[redacted]
3.4.6	Water consumption	[redacted]
3.4.7	Ophthalmoscopic examination	[redacted]
3.4.8	Haematology	[redacted]
3.4.9	Differential blood count	[redacted]

Section A6.7/01/02/03 **Chronic Toxicity/Carcinogenicity (104 weeks)**
Annex Point IIA, VI.6.7 **Feeding Study in Rats**

3.4.10 Clinical Chemistry

3.4.11 Urinalysis

3.4.12 Pathology

3.4.12.1 Organ Weights

3.4.13 Histopathology

3.4.14 Other examinations

3.5 Statistics

3.6 Further remarks None

Section A6.7/01/02/03 Chronic Toxicity/Carcinogenicity (104 weeks)
Annex Point IIA, VI.6.7 Feeding Study in Rats

4 RESULTS AND DISCUSSION

[redacted]

4.1 Clinical signs

[redacted] *

4.2 Mortality

[redacted]

4.3 Body weight and body weight gain

[redacted]

4.4 Food consumption

[redacted]

4.5 Water consumption

[redacted]

Section A6.7/01/02/03 Chronic Toxicity/Carcinogenicity (104 weeks)

Annex Point IIA, VI.6.7 **Feeding Study in Rats**

4.6 Ophthalmoscopic examination

4.7 Haematology



Section A6.7/01/02/03 **Chronic Toxicity/Carcinogenicity (104 weeks)**
Annex Point IIA, VI.6.7 **Feeding Study in Rats**

4.8 Clinical Chemistry



Section A6.7/01/02/03 Chronic Toxicity/Carcinogenicity (104 weeks)

Annex Point IIA, VI.6.7 **Feeding Study in Rats**

4.9 Cholinesterase activity

4.10 Urinalysis

4.11 Organ Weights



Section A6.7/01/02/03 **Chronic Toxicity/Carcinogenicity (104 weeks)**

Annex Point IIA, VI.6.7 **Feeding Study in Rats**

4.12 Pathology



Section A6.7/01/02/03 **Chronic Toxicity/Carcinogenicity (104 weeks)**
Annex Point IIA, VI.6.7 **Feeding Study in Rats**

4.12 Pathology (contindued)



Section A6.7/01/02/03 Chronic Toxicity/Carcinogenicity (104 weeks)

Annex Point IIA, VI.6.7 **Feeding Study in Rats**

5 APPLICANT'S SUMMARY AND CONCLUSION

5.1 Materials and methods

5.2 Results and discussion



5.3 Conclusion

5.3.1 LOAEL — 40 mg/kg bw/day in both sexes based on reduced mean body weight at 40 mg/kg bw/day

5.3.2 NOAEL — 20 mg/kg bw/day

5.3.3 Reliability

5.3.4 Deficiencies

Section A6.7/01/02/03 Chronic Toxicity/Carcinogenicity (104 weeks)

Annex Point IIA, VI.6.7 **Feeding Study in Rats**

	Evaluation by Competent Authorities
	Use separate "evaluation boxes" to provide transparency as to the comments and views submitted
	EVALUATION BY RAPPORTEUR MEMBER STATE
Date	[redacted]
Materials and Methods	[redacted]
Results and discussion	[redacted]
Conclusion	[redacted]
Reliability	[redacted]
Acceptability	[redacted]
[redacted]	[redacted]













Section A6.7/04/05/06/07/08/09
Annex Point IIA, VI.6.7

Carcinogenicity
Feeding Study in Mice

1 REFERENCE

Official use only

1.1 Reference

A6.7/04:
[redacted] (1989): IPBC 78 Week Dietary Carcinogenicity Study in Mice Volume 1; [redacted] 16.06.1989

A6.7/05:
[redacted] (1989): IPBC 78 Week Dietary Carcinogenicity Study in Mice Volume 2; [redacted] 16.06.1989

A6.7/06:
[redacted] (1989): IPBC 78 Week Dietary Carcinogenicity Study in Mice Volume 2 continued to Volume 3; [redacted] 16.06.1989

A6.7/07:
[redacted] (1989): IPBC 78 Week Dietary Carcinogenicity Study in Mice Volume 3; [redacted] 16.06.1989

A6.7/08:
[redacted] (1995): Pathology Working Group (PWG) Report on the 78-Week Dietary Carcinogenicity Study of 3-Iodo-2-Propynyl Butyl Carbamate (IPBC) in CD-1 Mice [redacted] 02.02.1995

A6.7/09:
[redacted] (1988); Results of Dietary Analysis for IPBC for the 78-Week Study in Mice; [redacted] 01:03:1988

1.2 Data protection

[redacted]

1.2.1 Data owner

[redacted]

1.2.2 Companies with letter of access

[redacted]

1.2.3 Criteria for data protection

[redacted]

2 GUIDELINES AND QUALITY ASSURANCE

2.1 Guideline study

[redacted]

US EPA Pesticide Assessment Guidelines Subdivision F, 83-2 which is comparable to OECD 451

[redacted]

2.2 GLP

[redacted]

2.3 Deviations

None

Section A6.7/04/05/06/07/08/09
Annex Point IIA, VI.6.7

Carcinogenicity
Feeding Study in Mice

3 MATERIALS AND METHODS

3.1	**Test material**	[redacted]
3.1.1	Lot/Batch number	[redacted]
3.1.2	Specification	As given in section 2
3.1.3	Purity	[redacted]
3.1.4	Description	[redacted]
3.1.5	Stability	[redacted]
3.2	**Test Animals**	
3.2.1	Species	Mice
3.2.2	Strain	CD-1
3.2.3	Source	[redacted]
3.2.4	Sex	male, female
3.2.5	Age/weight at study initiation	[redacted]
3.2.6	Number of animals per group	[redacted]
3.2.6.1	at interim sacrifice	[redacted]
3.2.6.2	at terminal sacrifice	[redacted]
3.2.7	Control animals	[redacted]
3.3	**Administration/ Exposure**	Oral
3.3.1	Duration of treatment	[redacted]
3.3.2	Interim sacrifice(s)	[redacted]
3.3.3	Final sacrifice	[redacted]
3.3.4	Frequency of exposure	[redacted]
3.3.5	Postexposure period	[redacted]
3.3.6	Type	[redacted]
3.3.7	Concentration	[redacted]
3.3.8	Vehicle	[redacted]
3.3.9	Concentration in vehicle	[redacted] *
3.3.10	Total volume applied	[redacted]
3.3.11	Controls	[redacted]